1 COVID-19 Susceptibility and Severity Risks in a Survey of Over 500,000 People

Spencer C. Knight*¹, Shannon R. McCurdy*¹, Brooke Rhead¹, Marie V. Coignet¹, Danny S.
Park¹, Genevieve H.L. Roberts², Nathan D. Berkowitz¹, Miao Zhang¹, David Turissini¹, Karen
Delgado², Milos Pavlovic², AncestryDNA Science Team², Asher K. Haug Baltzell², Harendra
Guturu¹, Kristin A. Rand¹, Ahna R. Girshick¹, Eurie L. Hong¹, Catherine A. Ball¹

6

7 *These authors contributed equally to this work.

- 8 1. AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107
- 9 2. AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043
- 10 Corresponding Author: Catherine Ball, <u>cball@ancestry.com</u>
- 11

12 Abstract

13 The growing toll of the COVID-19 pandemic has heightened the urgency of identifying 14 individuals most at risk of infection and severe outcomes, underscoring the need to assess susceptibility and severity patterns in large datasets.¹ The AncestryDNA COVID-19 Study 15 16 collected self-reported survey data on symptoms, outcomes, risk factors, and exposures for over 17 563,000 adult individuals in the U.S., including over 4,700 COVID-19 cases as measured by a self-reported positive nasal swab test. We observed significant associations between several risk 18 19 factors and COVID-19 susceptibility and severity outcomes. Many of the susceptibility 20 associations were accounted for by differences in known exposures; a notable exception was 21 elevated susceptibility odds for males after adjusting for known exposures and age. We also 22 leveraged the dataset to build risk models to robustly predict individualized COVID-19 23 susceptibility (area under the curve [AUC]=0.84) and severity outcomes including 24 hospitalization and life-threatening critical illness amongst COVID-19 cases (AUC=0.87 and 25 0.90, respectively). The results highlight the value of self-reported epidemiological data at scale to provide public health insights into the evolving COVID-19 pandemic. 26

28 Main

29 The COVID-19 pandemic has resulted in nearly 35 million COVID-19 cases and more than 1.000.000 deaths worldwide,² including nearly 7.5 million cases and more than 210.000 deaths in 30 the United States as of early October 2020.³ The growing impact of the pandemic intensifies the 31 need for enhanced understanding of COVID-19 susceptibility and severity risk factors, not only 32 33 for public health experts, but also for individuals seeking to assess their own personalized risk. Prior research has hypothesized that differences in COVID-19 susceptibility are related to age,⁴ 34 sex-dependent immune responses,⁵ and genetics,^{6,7} while heightened *severity* of COVID-19 35 illness is associated with risk factors such as age,^{1,4,8,9} sex,^{5,10-12} underlying health 36 conditions,^{1,9,10,13,14} and genetic factors including the ABO blood group.¹⁵ Self-reported survey 37 38 data, which can easily be collected in the home, afford the opportunity to dynamically monitor the continually evolving pandemic and allow for real-time estimation of individual-level 39 COVID-19 risk.^{16–19} Furthermore, self-reported surveys allow for collection of information about 40 41 known exposures, of which few epidemiological COVID-19 studies have explicitly accounted for in association analyses to date.²⁰ 42

43

In this paper, we aim to provide insight into factors associated with susceptibility and severity of COVID-19 using a large survey cohort of 563,141 AncestryDNA customers who have consented to participate in the AncestryDNA COVID-19 Study (Supplementary Tables 1-6).⁶ We found that known exposure differences account for many associations for a positive COVID-19 test result.^{18,21} Further analysis yielded evidence that males may be more susceptible to COVID-19 than females after adjusting for known exposures and age. While several previous reports have documented increased severity risk in males,^{5,11,13} the finding of sex-based differences in

susceptibility here warrants further investigation. This study also replicates previous reports of strong associations between certain health conditions, age, and COVID-19 severity,^{1,8–14} many of which remain significant after adjusting for other risk factors. We additionally investigated the symptomotology of COVID-19, and found that the symptoms most strongly associated with a positive test result are distinct from the symptoms most strongly associated with severity.^{17,18,22,23}

56

57 Finally, we built predictive risk models for COVID-19 susceptibility and severity outcomes. For susceptibility, we designed two models and additionally applied two literature-based models¹⁸ to 58 59 predict COVID-19 cases among respondents reporting a test result. We also designed models to 60 predict two different COVID-19 severity outcomes based on minimal information about 61 demographics, health conditions, and symptoms: hospitalization due to COVID-19 infection 62 (referred to throughout as "hospitalization") and progression of an infection to a life-threatening 63 critical case among those reporting a positive COVID-19 result (referred to throughout as "critical case"; Methods).¹³ Both the susceptibility and severity models are robust and 64 65 generalizable across a large internal holdout set, and could potentially serve as tools for understanding individualized COVID-19 susceptibility and severity risk.^{1,16–19,24} 66

67

Survey description. Survey responses were collected from AncestryDNA customers (see Methods and Supplementary Table 3 for demographic information). The survey collected selfreported responses to questions about COVID-19 test results, 15 symptoms among those who tested positive or who tested negative and had flu-like symptoms, disease progression for positive testers, age, height, weight, known exposures to biological relatives, household members, patients or any other contacts with COVID-19, and 11 underlying health conditions (Supplementary Tables 1 and 2). Data were collected between 22 April 2020 and 6 July 2020,

- and the survey completion rate was approximately 95%. In general, the COVID-19 positive test
- rate and self-reported clinical outcomes are consistent with those reported by the U.S. Centers for
- 77 Disease Control and Prevention (CDC) over a similar period (Supplementary Note 1).²¹

79 Association Analyses

80 Susceptibility. We investigated associations between COVID-19 testers reporting a positive or 81 negative result and risk factors within the dataset (Figure 1, Methods, Supplementary Tables 7-82 12). Unadjusted odds ratios (ORs) were calculated using simple logistic regression, and adjusted 83 ORs (aORs) were calculated using multiple logistic regression including known exposures, age, 84 and sex as risk factors. Unadjusted ORs provide insight into which individual variables are 85 correlated with testing positive for COVID-19, while adjusted ORs provide insight into which of these associations are not completely explained due to differences in age, sex, and known 86 exposures.²⁵ 87

88 Known COVID-19 exposures, either through a household case (OR=26.03; 95% confidence 89 interval [CI]=(22.26, 30.43)), biological relative (OR=5.77; 95% CI=(4.99, 6.68)), or other 90 source of "direct" exposure (OR=6.94; 95% CI=(6.02, 7.99)) were the strongest predictors of a 91 positive COVID-19 test result (Figure 1, Supplementary Table 7). In general, adjusting for 92 known exposures, age, and sex resulted in attenuation of the ORs, with many associations 93 becoming insignificant after adjustment (Figure 1, Supplementary Tables 8-9). Intriguingly, the 94 OR for males was not attenuated after adjustment, and males remained at elevated odds after 95 adjusting for known exposures and age (aOR=1.36; 95% CI=(1.19, 1.55); Figure 1. 96 Supplementary Table 9). We also note that males and females reported comparable exposure 97 burden, with males slightly more likely to report a household case of COVID-19 but less likely 98 to report a case of COVID-19 among biological relatives (Supplementary Tables 11-12).

99

100 Younger individuals (ages 18-29; OR=1.51; 95% CI=(1.26, 1.81)), as well as individuals of 101 admixed African-European (OR=1.48; 95% CI=(1.18, 1.85)) or admixed Amerindian ancestry 102 (OR=1.49; 95% CI=(1.26, 1.77)) were significantly more likely to test positive compared to 103 older individuals (ages 50-64, the largest age group in this cohort) or those of European ancestry, 104 respectively (Supplementary Table 7). These individuals reported higher levels of COVID-19 105 cases within the household, cases among biological relatives, and/or other known "direct" COVID-19 exposures (Supplementary Tables 10-12).²⁶⁻³⁰ Adjusting for age, sex, and known 106 107 exposures attenuated the OR for all three of these groups (younger aOR=1.28; 95% CI=(1.03, 108 1.59), African-European aOR=1.23; 95% CI=(0.94, 1.62), and Amerindian aOR=1.27; 95% 109 CI=(1.04, 1.57); Figure 1, Supplementary Table 9).

110

111 Individuals reporting pre-existing medical conditions (e.g., cancer, cardiovascular disease, 112 chronic kidney disease [CKD], diabetes, hypertension) were less likely to test positive for 113 COVID-19 (Figure 1, Supplementary Table 7). We observed significantly decreased odds of a 114 known "direct" exposure to COVID-19, as well as significantly decreased odds of a household 115 case of COVID-19, among such individuals relative to those without any health conditions 116 (OR=0.71; 95% CI=(0.65, 0.78) and OR=0.74; 95% CI=(0.65, 0.84), respectively;117 Supplementary Tables 10-11). Notably, individuals with asthma and those with other lung 118 conditions had significantly decreased odds of testing positive after adjusting for known 119 exposures, age, and sex (OR=0.82; 95% CI=(0.69, 0.97) and OR=0.67; 95% CI=(0.44, 1.00), 120 respectively; Supplementary Table 9).

121

122 Severity. We investigated associations between demographics, exposures, symptoms, and 123 underlying health conditions for hospitalization and critical illness progression among COVID-19 cases (Figure 2, Supplementary Figure 1). Consistent with previous reports,^{1,9,12–14} we 124 125 observed positive associations between certain health conditions and COVID-19 severity 126 outcomes; many of these associations remained significant after adjustment for age, sex, and obesity (BMI >= 30) (Figure 2, Supplementary Tables 13-16). COVID-19 cases reporting at least 127 128 one underlying health condition were significantly more likely to progress to a critical case 129 (OR=2.85; 95% CI=(1.78, 4.57); Figure 2, Supplementary Figure 1, Supplementary Table 15). 130 Specific underlying health conditions that were associated with hospitalization and/or critical 131 case progression included CKD, chronic obstructive pulmonary disease (COPD), diabetes, 132 cardiovascular disease, and hypertension (Figure 2, Supplementary Figure 1, Supplementary 133 Tables 13 and 15). Among individuals testing positive for COVID-19, the oldest (≥ 65 years) 134 were significantly more likely to be hospitalized compared to those aged 50-64 (OR=1.70; 95% 135 CI=(1.13, 2.56); Figure 2, Supplementary Table 13). Individuals of admixed African-European 136 ancestry who tested positive were significantly more likely to report progression to a critical 137 case, compared to those with European ancestry (OR=2.07; 95% CI=(1.03, 4.17); Supplementary 138 Figure 1, Supplementary Table 15). Among COVID-19 cases, males were significantly more 139 likely than females to report progression to a critical case (OR=1.54, 95%; CI=(1.00, 2.37); 140 Supplementary Figure 1, Supplementary Table 15); these findings are consistent with CDC reports of increased ICU admittance rates in males (3% vs. 2%).²¹ 141

143 **Differential symptomology.** Among symptomatic people who were reported a COVID-19 test 144 result, those reporting moderate to severe change in taste or smell (OR=7.26; 95% CI=(5.54, 145 9.50)), fever (OR=1.60; 95% CI=(1.28, 2.01)), or feeling tired or fatigue (OR=1.41; 95% 146 CI=(1.05, 1.89)) were more likely to test positive (Figure 3, Supplementary Table 7). Those 147 reporting moderate to severe runny nose (OR=0.59; 95% CI=(0.47, 0.75)) or sore throat (OR=0.49; 95% CI=(0.39, 0.62)) were more likely to test negative, consistent with previous 148 149 reports that these symptoms are more indicative of influenza or the common cold (Figure 3, Supplementary Table 7).^{17,18,22} Change in taste or smell, a hallmark symptom of COVID-19 150 151 infection, was not associated with hospitalization (OR=0.77, 95% CI=(0.55, 1.07); Figure 3, 152 Supplementary Table 13). By contrast, dyspnea (shortness of breath) was the most predictive of 153 hospitalization and critical case progression (OR=7.52; 95% CI=(4.92, 11.49) and OR=11.55; 95% CI=(5.91, 22.59), respectively),²³ but was not associated with a positive test result 154 155 (OR=1.14; 95% CI=(0.91, 1.44); Figure 3, Supplementary Tables 7, 13, and 15).

Predictive risk models. We developed models that predict an individual's COVID-19 risk (positive test result or severity). Many predictive models for COVID-19 infection and severity outcomes have been reported in the literature.^{1,16–18,24,31} To date, few large-scale studies have investigated both susceptibility and severity risk within the same dataset, offering a consistent and comprehensive understanding of similarities and differences between the two outcomes.

For each of the risk models we developed, the survey data were divided into independent training and test cohorts, and additional association analyses were performed on the training data to guide the selection of risk factors for the models (Methods, Supplementary Tables 17-20). In contrast to association analyses, these risk models are based on penalized logistic regression with crossvalidation in order to allow for transferability to independent cohorts.

167 The susceptibility models were designed to predict a COVID-19 result (positive or negative) 168 from risk factors among testers. In addition to our own two models, we also replicated two self-169 reported models from the literature in order to assess how well our models perform relative to a respected benchmark.¹⁸ In all, we compared four models: our model based on demographics and 170 171 exposures (referred to throughout as "Dem + Exp"); our model based on demographics, 172 exposures, and symptoms (referred to throughout as "Dem + Exp + Symp"); and the two 173 literature-based models designed with nearly identical risk factors as reported previously in 174 another large, self-reported study ("How We Feel" (HWF); models referred to as "HWF Exp + Symp" and "HWF Symp" throughout; Supplementary Note 2, Supplementary Table 20).¹⁸ 175

176

All four susceptibility models performed robustly, with the Dem + Exp + Symp model achieving
the highest overall performance (Figure 4, Supplementary Tables 21-24). The three models that

179 included one or more symptoms outperformed the model without symptoms (Dem + Exp), 180 underscoring the value of self-reported symptoms for discriminating between cases and controls. 181 The Dem + Exp model had an area under the curve (AUC) of 0.84 + - 0.02, and the most predictive risk factor was having a household case of COVID-19. The Dem + Exp + Symp 182 183 model had an AUC of 0.94 ± 0.02 , and the most predictive symptom was change in taste or 184 smell. The HWF Exp + Symp model had an AUC of 0.90 +/- 0.03, and the HWF Symp model 185 had an AUC of 0.87 + -0.03 (Supplementary Note 3). Each of the models performed comparably 186 across different age, sex, and genetic ancestry groups (Supplementary Tables 21-24). We 187 observed no significant overfitting in any of the models as evidenced by comparable train-test 188 performances (Supplementary Table 25).

189

190 We also trained severity models to predict hospitalization and critical illness progression among 191 COVID-19 cases. We included a number of risk factors and symptoms most associated with 192 severe COVID-19 outcomes from the literature and/or our training dataset (Figure 3, Supplementary Tables 18 and 19); these included age,^{1,8,9,13} sex,^{1,5,11–13} morbid obesity (BMI >= 193 40),^{1,32} and health conditions,^{1,9,12-14} as well as shortness of breath,²³ fever, feeling tired or 194 195 fatigue, dry cough, and diarrhea for symptoms. Both models performed robustly on an 196 independent holdout dataset (Figure 4). The hospitalization model had an AUC of 0.87 ± 0.03 , 197 and the critical case model had an AUC of 0.90 ± 0.03 . For both severity models, shortness of 198 breath was the most predictive risk factor. We were concerned that this might seem obvious, so 199 we designed models excluding this symptom which also achieved moderately high 200 discriminative performance (AUC > 0.80; Supplementary Figure 4). The severity models 201 performed comparably when stratifying by age, sex, and genetic ancestry (Supplementary Tables

202 26-27), and there was no significant overfitting bias as evidenced by comparable train-test
203 performances (Supplementary Table 25).

204

In contrast with susceptibility models, we did not evaluate the severity models against literaturebased models, as the vast majority of these models include clinical factors (e.g., bloodwork) not measured in this self-reported dataset.^{1,16,31} However, the models presented here perform on par with many previously reported models despite the absence of clinical factors, suggesting the potential value of self-reported data to identify the most at-risk COVID-19 individuals.^{16,31}

210

211 Discussion. The AncestryDNA COVID-19 Study provides a highly complete, self-reported 212 dataset that contains information about a plethora of risk factors in the context of COVID-19 213 susceptibility and severity outcomes. The self-report framework provides fast, low-cost, 214 population-scale data that are particularly valuable in a pandemic, where knowledge is both 215 limited and evolving rapidly based on changing circumstances. Additionally, the broad collection 216 mechanism enables data-gathering from many more and potentially more diverse participants 217 than typically seen in a medical setting, and participants can safely provide data from their homes. Moreover, self-reported data have been shown to be useful for estimating population 218 219 prevalence,¹⁹ and models built from these data may help to contextualize individual risk prior to infection with COVID-19.^{1,16–18,24,31} 220

221

The study highlights exposure burden as the primary risk factor for COVID-19 susceptibility, and the importance of accounting for known exposures when assessing differences in susceptibility to COVID-19. Few studies have measured and explicitly adjusted for known

COVID-19 exposures at this scale.²⁰ We found elevated exposure levels for younger individuals, 225 226 as well as individuals of admixed African-European or admixed Amerindian ancestry, which 227 account for at least some of the elevated susceptibility risk for these individuals as evidenced by 228 attenuation of ORs after adjustment for known exposures and age. This finding is consistent with 229 previous reports about elevated exposure levels for younger and minority groups within the U.S.^{26–30} By contrast, we found reduced exposure levels among those reporting one or more pre-230 231 existing health conditions. The lower exposure burden observed for these individuals may reflect 232 pre-pandemic differences in public interactions or increased precautions to mitigate exposure, given published severity risks associated with these conditions.^{1,9,13,14,33,34} 233

234

Importantly, we found elevated susceptibility risk in males after adjusting for age and known exposures, and the adjusted odds were not attenuated compared to the unadjusted odds. This finding is distinct from previous findings on elevated severity risk in males.^{1,5,11} This result could be due to differences between men and women in behaviors, unknown exposures, biology, genetics,^{5–7} or other risk factors not measured within this dataset.

240

Another major contribution of this study is the development of novel risk models for predicting an individual's COVID-19 susceptibility and severity risk. The risk models presented here perform comparably or better than similar and more complex models reported previously.^{16–} ^{18,24,31} This study is also one of few to date to assess and demonstrate relatively strong performance of risk models across different age, sex, and genetic ancestry groups,¹⁷ highlighting the potential utility and generalizability of these models to broader populations. Such models may be useful to clinicians to estimate an individual's risk of infection and/or severity risk, or as

a potential tool to triage testing given limited resources.^{17,18,22} Just as importantly, the models
could also be used by public health experts to understand population-level risk at large, given
minimal self-reported risk factor data.

251

The COVID-19 pandemic has exacted a historic toll on healthcare systems and global economies, and continues to evolve based on changes in human behavior, public health guidelines, and societal factors. The large AncestryDNA network, well-established data collection mechanisms, and willingness of AncestryDNA customers to participate in COVID-19 research have rapidly come together in this study to elucidate more details about susceptibility and severe disease risk factors and help point the way to minimizing disease burden.

258

260 Methods

- 261 Ethics statement. Ethics statement. All data for this research project were from subjects who
- 262 have provided informed consent to participate in AncestryDNA's Human Diversity Project, as
- 263 reviewed and approved by our external institutional review board, Advarra (formerly Quorum).
- All data were de-identified prior to use.

Study population. Collection of self-reported COVID-19 outcomes from AncestryDNA customers who consented to research, participation criteria for the study, and the survey design are described in a genome-wide association study (GWAS) on a very similar AncestryDNA dataset, which identified three novel, genome-wide significant loci.⁶ Here, participants reporting a negative test result were also assessed for symptoms and clinical outcomes. Analyses presented here were performed with data collected between 22 April and 6 July 2020.

Outcome definitions. The study assessed three outcomes: one for susceptibility and two for severity of COVID-19 infection. Cases for COVID-19 susceptibility were individuals who responded, "Yes, and was positive" to the question, "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" Responders who answered, "Yes, and was negative" were used as controls for the susceptibility analysis.

The hospitalization outcome was defined among COVID-19-positive cases if a participant responded "Yes" to a binary question about experiencing symptoms due to COVID-19 illness and "Yes" to the hospitalization question ("Were you hospitalized due to these symptoms?). Controls were defined by a response of "No" to the hospitalization question in addition to reporting a self-reported positive COVID-19 test result.⁶

281

282 Critical cases of COVID-19 were defined via a response of "Yes" to one or more questions about 283 ICU admittance ("Were you hospitalized in the Intensive Care Unit [ICU] with a ventilator?" or 284 "Were you hospitalized in the Intensive Care Unit [ICU] with oxygen?") or, alternatively, self-285 reported septic shock, organ failure, or respiratory failure resulting from a COVID-19 infection 286 ("Have you had any of the following complications due to your illness? Select all that apply.").¹³

287 Controls were defined by a response of "No" across all of these questions in addition to self288 reporting a positive COVID-19 test result.

289

Genetic sex and ancestry definitions. All individuals were genotyped, using previously described general genotyping and quality control procedures.³⁵ Both sex and genetic ancestry were defined for individuals based on their genotypes. Genetic ancestry was estimated using a proprietary algorithm to estimate continental admixture proportions.³⁶ Briefly, this algorithm uses a hidden Markov model to estimate unphased diploid ancestry across the genome by comparing haplotype structure to a reference panel.

296

Data preparation for analysis. Multiple-choice categorical questions were one-hot ("dummy") encoded as binary risk factors with k-1 degrees of freedom, where k corresponds to the number of fields for a given question. In this framework, a value of 0 across all k-1 fields corresponds to a response of "None" or "None of the above" for a given question.

301

We considered several risk factors and outcomes questions in our association analyses and risk modeling efforts, some of which are summarized in Supplementary Tables 1 and 2. Based on the dependency structure within our survey, not every question was surfaced to every participant included within our study. As such, we made the following inferences:

Participants reporting "No" to a binary question about symptoms arising from COVID-19
 infection ("Did you experience symptoms as a result of your condition?") were
 designated as negatives for dependent questions about individual symptoms ("Between
 the beginning of February 2020 and now, have you had any of the following

310	symptoms?"), hospitalization due to symptoms ("Were you hospitalized due to these
311	symptoms?"), ICU admittance due to symptoms ("Were you hospitalized in the Intensive
312	Care Unit [ICU] with a ventilator?" or "Were you hospitalized in the Intensive Care Unit
313	([ICU] with oxygen?"), and medications prescribed due to symptoms ("Did a doctor treat
314	you with medication for your illness?")
315 •	Participants reporting "No" to a binary question about hospitalization ("Were you
316	hospitalized due to these symptoms?") were assigned to a hospital duration of 0 days and
317	designated as negative for ICU admittance due to symptoms.
318 •	Participants reporting "No" to a binary question about medications prescribed due to
319	symptoms ("Did a doctor treat you with medication for your illness?") were designated as
320	negative for individual medication fields from a dependent question ("What medication
321	were you treated with?").

322

Responses to a question about individual symptoms ("Between the beginning of February 2020 and now, have you had any of the following symptoms?") were converted to a binary variable based on the following mapping: 0 = None, Very Mild, Mild; 1 = Moderate, Severe, Very Severe.

327 Association analysis. Analyses were performed either with the *statsmodels* package in Python3 328 or in base R with the *glm* function. For each susceptibility and severity outcome and risk factor 329 of interest, a simple logistic regression (LR) model was fit using unpenalized maximum likelihood.³⁷ LR models were fit on the entire cohort, except for age, sex, genetic ancestry, and 330 331 obesity, where the models were fit only on the appropriate reference population drawn from the 332 entire cohort (Supplementary Tables 7-16). Multiple logistic regression was used to adjust the 333 ORs for known COVID-19 exposures and potentially confounding risk factors. The adjusted 334 model includes age, sex, and four known exposures for susceptibility outcomes (Y/N if any); and 335 age, sex, obesity (binarized if $BMI \ge 30$), and health conditions (binarized if any) for severity 336 outcomes (Figures 1 and 2).

337

For each risk factor, 95% confidence intervals (CIs) for the log odds ratio were estimated under
the normal approximation. The significance threshold was Bonferroni-corrected for the 42
different risk factors examined, leading to an adjusted threshold of 0.05/42=0.0012.³⁷

342 **Risk model training and evaluation**

Data splitting. All data were used in the OR analyses; data splitting was performed for risk modeling only. Prior to model training, the data were split with a fixed random seed. For susceptibility models without symptoms, 75% of the data were used for model training and 25% of the data were used for holdout evaluation. For severity models and susceptibility models with symptoms, 50% of the data were used for model training and 50% of the data were used for holdout evaluation. The larger holdout set allows for more robust stratified analyses of model performances, given the smaller overall cohort sizes for models with symptoms.

350

351 Predictive risk models. Logistic regression models were trained and evaluated using the *scikit-learn* package in Python. Here, we used lasso-penalized multiple logistic regression with cross-353 validation on the training dataset in order to select an optimal hyperparameterization for 354 generalizability to independent test sets.³⁷ The penalized objective function for regression was 355 weighted by inverse prevalence to address class imbalance and was framed as follows:

356

357
$$Cost(\boldsymbol{\beta}) = -\frac{1}{m} \sum_{j=1}^{m} \left(\frac{m}{m_{y=yj}} \right) y_j Ln \left(Logistic(\boldsymbol{\beta} \cdot \boldsymbol{x}_j) \right) + \left(\frac{m}{m_{y=yj}} \right) (1 - y_j) Ln \left(1 - Logistic(\boldsymbol{\beta} \cdot \boldsymbol{x}_j) \right) +$$
358
$$\frac{\lambda}{m} \sum_{i=0}^{n} |\beta_i|$$

359

where *m* is the number of training examples, y_j is the true value of the outcome variable for the *jth* observation within the training data, $m_{y=yj}$ is the number of training examples with $y=y_j$, β corresponds to the vector of estimated coefficients for the risk factors, x_j is the vector of risk factor values for the *jth* observation within the training data, *Logistic* is the logistic (sigmoid) function, λ is the regularization parameter which favors simpler models via shrinkage of the beta

365 coefficients, *n* is the total number of risk factors in the model, β_i is the regression coefficient for 366 the *ith* risk factor in the model, and *Ln* is the natural logarithm.

367 Risk factor selection and model training. We chose risk factors based on a minimal subset of nominally significant ORs within our training data as well as literature guidance.^{1,4,5,9,11–14} For 368 369 the susceptibility models without symptoms, we included a subset of exposure-related questions, 370 based on the training OR analyses, as well as two demographic variables (age and sex). For 371 susceptibility models with symptoms, we additionally included the five symptoms most 372 differentiated between symptomatic negative and positive testers from our training ORs. For the 373 severity models, we included pre-existing conditions, based on the training OR analyses, predictive symptoms within our training dataset³⁶, morbid obesity (BMI ≥ 40), age, and sex. 374 375 The full list of risk factors for each model is included in Supplementary Table 20.

376

Once final risk factors were selected, we performed 5-fold cross-validation with grid search on our training dataset to select an optimal lasso regularization parameter lambda.³⁷ For the grid search, we scanned 8 different values for lambda, equally partitioned geometrically across a 4log space. We then re-trained on the entire training dataset with the optimal lambda, and evaluated the final model on the holdout dataset.

382

383 **Model thresholding.** Phenotypes were predicted from the output of trained models based on a 384 50% probability threshold (i.e., logistic model output > 0.5). Sensitivity and specificity were then 385 calculated based on the true vs. predicted binary outcomes.

386

Estimation of performance error. To estimate the error in our model performances, we bootstrapped our holdout dataset 1,000 times to generate a sampling distribution for each evaluation metric. We estimated the mean and 95% CIs for each metric based on the mean and standard deviation of this sampling distribution.³⁷

391

- 392 Figures, Tables, and Legends
- 393 Figures

Figure 1: Odds ratio visualization for susceptibility



398 Figure 1. Susceptibility odds ratios (ORs) and 95% confidence intervals (CIs) estimated 399 from simple ("Unadjusted models," grey) and multiple ("Adjusted models," black) logistic 400 regression with adjustment for other risk factors. Open circles indicate not significant (p-401 value > 0.05) after accounting for multiple hypothesis tests using Bonferroni correction. Age, 402 sex, genetic ancestry, and obesity ORs were estimated in relation to the reference variables 403 indicated. Exposure, health, and symptom ORs were each estimated separately as binary 404 variables. Symptom ORs were estimated as binary variables among symptomatic testers only 405 (Methods). Risk factor adjustments for susceptibility include: sex, age, and at least one known 406 COVID-19 exposure (Methods).

407

409 **Figure 2:** Odds ratio visualization for severity



Severity - Hospitalization



413 Figure 2. Severity (hospitalization) odds ratios (ORs) and 95% confidence intervals (CIs) 414 estimated from simple ("Unadjusted models," grey) and multiple ("Adjusted models," 415 black) logistic regression with adjustment for other risk factors. Open circles indicate not 416 significant (p-value > 0.05) after accounting for multiple hypothesis tests using Bonferroni 417 correction. Age, sex, genetic ancestry, and obesity ORs were estimated in relation to the 418 reference variables indicated. Exposure, health, and symptom ORs were each estimated 419 separately as binary variables. Symptom ORs were estimated as binary variables among 420 symptomatic testers only (Methods). Risk factor adjustments for severity include: sex, age, 421 obesity (Y/N), and underlying health conditions (Y/N if any). See Supplementary Figure 1 for 422 critical case severity ORs.



424 **Figure 3**: Comparison of susceptibility and severity adjusted ORs



Figure 3. Comparison of susceptibility adjusted ORs (horizontal axis) and severity adjusted ORs (vertical axis) for symptoms in Figures 1 and 2. Severity aORs are for hospitalization. Note that aORs for susceptibility and severity are adjusted differently according to descriptions in Figure 1 and 2 captions. Adjusted ORs are plotted on a log scale for visibility. Shortness of breath is the strongest indicator of increased severity, while change in taste or smell is the

- 432 strongest indicator for testing positive for COVID-19 among symptomatic individuals
- 433 (Methods). See Supplementary Figure 2 for demographic, health condition, and exposure aORs.

435 **Figure 4:** Risk model performance



437

Figure 4. Performance of risk models on independent holdout data. a) Receiver operating characteristic (ROC) curves for susceptibility models to predict COVID-19 cases among testers reporting a result (positive or negative). b) Classification confusion matrix for susceptibility model with five predictive symptoms included. c) Classification confusion matrix for susceptibility model without symptoms. d) Classification confusion matrix for literature-based susceptibility model with three risk factors including change in taste or smell. e) Classification confusion matrix for literature-based susceptibility model with seven COVID-19 symptoms. f)

445 ROC curves for severity models to predict either hospitalization (red) or critical illness 446 progression (black) among COVID-19 cases. g) Classification confusion matrix for the 447 hospitalization risk model. h) Classification confusion matrix for the critical case risk model. 448 Refer to Methods as well as Supplementary Tables 20-27 for additional model performance data 449 and model risk factor information. 450

Data availability We plan to make a dataset available to qualified scientists through the European Genome-phenome Archive (EGA). The EGA dataset includes the risk factors and outcomes studied here, for a different set of individuals.

455 Acknowledgements We thank our AncestryDNA customers who made this study possible by 456 contributing information about their experience with COVID-19 through our survey. Without 457 them, this work would not be possible. We would like to thank Zach Bass, Robert Dowling, 458 Disha Akarte, Swapnil Sneham, Sean Enright and the entire Cyborg team for their tireless work 459 in the release and continued support of the COVID-19 survey.

460 Author contributions SCK and SRM contributed equally to the manuscript and wrote the first 461 draft of the paper. ARG provided direct project guidance and lead the COVID-19 research teams. SCK, SRM, BR performed the association analyses. SCK developed and assessed the risk 462 463 models. MVC and KAR designed the COVID-19 survey questionnaire. SCK and DP supported 464 the dataset creation. GHLR supported the phenotype definitions. MVC and NDB built the 465 demographic tables. SCK, SRM, BR, MVC, GHLR, ARG, and KAR helped with additional 466 analyses and interpretation. MZ, DP, DT, KD, MP, HG, AKHB helped with the EGA dataset. 467 The AncestryDNA Science Team contributed to additional work, allowing for the completion of 468 the COVID-19 research and manuscript. KAR, ELH, and CAB provided additional project 469 guidance. All authors contributed to the final manuscript.

- 470 Competing interests The authors declare competing financial interests: authors affiliated with471 AncestryDNA may have equity in Ancestry.
- 472 AncestryDNA Science Team: Yambazi Banda, Ke Bi, Robert Burton, Marjan Champine, Ross
 473 Curtis, Abby Drokhlyansky, Ashley Elrick, Cat Foo, Michael Gaddis, Jialiang Gu, Shannon
- 474 Hateley, Heather Harris, Shea King, Christine Maldonado, Evan McCartney-Melstad, Alexandra
- 475 McFarland, Patty Miller, Luong Nguyen, Keith Noto, Jingwen Pei, Jenna Petersen, Scott Pew,
- 476 Chodon Sass, Josh Schraiber, Alisa Sedghifar, Andrey Smelter, Sarah South, Barry Starr, Cecily
- 477 Vaughn, Yong Wang

478 Supplementary Materials

479

480 Supplementary Notes

481

482 Supplementary Note 1. Comparison of AncestryDNA Data to CDC Data. In general, the 483 COVID-19 testing results are consistent with those reported by the U.S. Centers for Disease Control and Prevention (CDC) over a similar period.²¹ For example, the CDC reported a 12% 484 485 cumulative overall positive test rate from 1 March to 30 May 2020, while 14.1% of 486 AncestryDNA survey participants reported testing positive (the denominator includes tests with 487 "results pending"). For hospitalization, the CDC reported that 14% of individuals testing positive 488 for COVID-19 were hospitalized, and 2% were admitted to an intensive care unit (ICU), between 489 22 January and 30 May 2020. Among the AncestryDNA survey respondents, 11% of those 490 reporting a positive COVID-19 test were hospitalized, and 4.9% were admitted to ICU between 491 22 April and 6 July 2020.

492

493 Supplementary Note 2. Risk factors for predictive susceptibility models. The HWF Exp + 494 Symp model includes three risk factors, including two exposures and one symptom (change in 495 taste or smell, Supplementary Table 20). The HWF Symp model includes seven symptoms most commonly associated with COVID-19 according to the CDC (Supplementary Table 20).^{18,38} For 496 497 the Dem + Exp and Dem + Exp + Symp models, we incorporated responses to several exposure 498 questions that were primary risk factors in the OR analysis of the training set (Methods and Supplementary Table 20).^{18,39,40} We also considered age and sex, given their nominal association 499 500 with COVID-19 in our ORs in the training dataset, as well as reports about these variables as

501 risk factors (Supplementary Table 17).^{4,5,30} For Dem + Exp + Symp model, we selected the most 502 differentiated symptoms between cases and controls amongst symptomatic COVID-19 testers 503 within the training dataset (Supplementary Table 17), including fever, change in taste or smell, 504 feeling tired/fatigued, runny nose, and sore throat.^{17,18,22}

505

506 Supplementary Note 3. Comparison of Ancestry and HWF Cohorts and Performances. The 507 HWF models performed better when trained and evaluated on the AncestryDNA dataset as 508 compared with the HWF dataset, particularly for the symptoms-only model (HWF Symp: 509 AncestryDNA-trained AUC=0.87 and HWF-trained AUC=0.76 and HWF Exp + Symp: AncestryDNA-trained AUC=0.90 and HWF-trained AUC=0.87; Figure 4).¹⁸ This result could be 510 511 due to differences in survey flow design, demographics, or the relative prevalences of self-512 reported symptoms between the two datasets. We re-trained and evaluated our models on a 513 subset of symptomatic COVID-19 testers (positives and negatives) reporting at least one 514 symptom of moderate or greater intensity. The performances of all models that included 515 symptoms were slightly attenuated in this cohort, with AUCs for the HWF models approaching 516 previous reports (HWF Symp: AncestryDNA-trained AUC=0.80 and HWF Exp + Symp: 517 AncestryDNA-trained AUC=0.87); the model without symptoms performed the same 518 (Supplementary Figure 3). This suggests that predicting COVID-19 cases on the basis of 519 symptoms alone is more challenging when symptoms are less differentiated between positive and 520 negative testers.

521

523 Supplementary Tables

524 Supplementary Table 1. Selected subset of survey questions considered in the context of

- 525 COVID-19 severity outcomes analysis and modeling efforts.
- 526

Risk factor description	Question	Possible responses		
COVID-19 test result	Have you been swab tested for COVID-19, commonly referred to as coronavirus?	Yes, and was positive; Yes, and was negative; Yes, and my results are pending; No, but I have had flu-like symptoms with a fever at some point since the beginning of February 2020; No, and I have not had flu-like symptoms at some point since the beginning of February 2020		
Case amongst direct biological relatives (multi- choice)	Have any of your biological relatives tested positive for COVID-19? Select all that apply.	Grandparent(s); Parent(s); Child(ren); Sibling(s); Other; None		
Healthcare worker routinely exposed to COVID-19	Are you a healthcare professional working directly with or in close physical proximity to patients who have tested positive for COVID-19?	Yes; No; Not sure		
Household case of COVID-19	Has someone in your household tested positive for COVID- 19?	Yes; No; Not sure		
Number of household cases of COVID-19	How many people in your household have tested positive for COVID-19?	Numeric		
Known direct COVID-19 exposure	Have you been directly exposed to someone who has tested positive for COVID-19?	Yes; No; Not sure		
Health condition(s)	Do you currently have any of the following health conditions? Select all that apply.	Asthma,COPD (Chronic Obstructive Pulmonary Disease); Other lung condition; Cancer (treated in the past year); Cardiovascular disease; Chronic kidney disease; Diabetes; Hypertension; Organ failure requiring a transplant (in the last year); Blood disorder requiring hematopoietic stem cell / bone marrow transplant; Other autoimmune disease; Other immunodeficiency disorder; Other; None; Not sure		

527

528 The survey flow was as described previously,⁶ with the addition of symptom and clincial 529 assessment for negative testers.

530 Supplementary Table 2. Selected risk factors considered in susceptibility or severity

531 outcomes analysis and modeling efforts.

532

Risk factor description	Ouestion	Possible responses		
COVID-19 test result	Have you been swab tested for COVID-19, commonly referred to as coronavirus?	Yes, and was positive; Yes, and was negative; Yes, and my results are pending; No, but I have had flu-like symptoms with a fever at some point since the beginning of February 2020; No, and I have not had flu-like symptoms at some point since the beginning of February 2020		
Symptoms (binary)	Did you experience symptoms as a result of your condition?	Yes; No; Not sure		
Symptoms (multi- choice)	Between the beginning of February 2020 and now, have you had any of the following symptoms?	Fever; Shortness of breath; Dry cough; Nasal congestion; Runny nose; Sore throat; Feeling tired or fatigue; Chills; Body aches; Headache; Cough producing phlegm; Abdominal pain; Nausea or vomiting; Diarrhea; Change in taste or smell		
Symptom duration (multi- choice)	How long did these symptoms last?	Less than 1 day; 1-3 days; 4-7 days; 8-14 days; 2 weeks to a month; 1-3 months; More than 3 months		
Hospitalization	Were you hospitalized due to these symptoms?	Yes; No; Not sure		
Hospital duration	How long were you hospitalized?	Numeric		
ICU with ventilator	Were you hospitalized in the Intensive Care Unit (ICU) with a ventilator?	Yes; No; Not sure		
ICU with oxygen	Were you hospitalized in the Intensive Care Unit (ICU) with oxygen?	Yes; No; Not sure		
Illness complications (multi-choice)	Have you had any of the following complications due to your illness? Select all that apply.	None; Pneumonia; Severe pneumonia leading to hospitalization; Respiratory failure; Septic shock; Multiple organ dysfunction or failure; Blood clots; Stroke; Other		

533

The survey flow was as described previously,⁶ with the addition of symptom and clincial assessment for negative testers.

536

537

539 Supplementary Table 3. Study population demographic summary

540

	COVID-19 Nasopharyngeal Swab Test Positive	COVID-19 Nasopharyngeal Swab Test Negative	Full AncestryDNA COVID-19 Cohort
	<i>n</i> = 4,726	<i>n</i> = 28,872	n = 563,141
Age			
Median, mean (sd)	49, 49.49 (15.43)	53, 52.68 (15.5)	56, 53.90 (16.13)
Bins (Counts, %)			
18-30	600 (0.13)	2496 (0.09)	52580 (0.09)
31-40	941 (0.2)	5001 (0.17)	87261 (0.15)
41-50	926 (0.2)	5333 (0.18)	90473 (0.16)
51-60	1057 (0.22)	6009 (0.21)	108062 (0.19)
61-70	735 (0.16)	5961 (0.21)	128200 (0.23)
71-90	467 (0.10)	4072 (0.14)	96565 (0.17)
Genetic Sex (counts, %)			
Female	3013 (0.64)	19945 (0.69)	380349 (0.67)
Male	1706 (0.36)	8867 (0.31)	183153 (0.32)
Genetic Ancestry Continental Groupings			
Admixed African-European ancestry	275 (0.06)	1244 (0.04)	17019 (0.03)
Admixed Amerindian ancestry	520 (0.11)	2336 (0.08)	36865 (0.07)
European ancestry	3026 (0.64)	20269 (0.7)	424328 (0.75)
Other ancestry	905 (0.19)	5023 (0.17)	84929 (0.15)
Pre-existing health conditions (any)	1911 (0.46)	15261 (0.55)	255788 (0.47)
BMI (med, mean, sd)	28.59, 29.83 (7.04)	28.67, 29.92 (7.05)	28.29, 29.53 (6.87)
Underweight (count, %)	<100	204	4407
Healthy (count, %)	971	6442	139565
Overweight (count, %)	1225	8503	172941
Obese (count, %)	1629	11264	203325
Flu			
Shot (yes)	2656 (0.63)	19856 (0.71)	356144 (0.65)
Test Dx (yes)	198 (0.05)	1180 (0.04)	11726 (0.02)
Symptoms (tested pos.)			
General, yes (count, % of pos.)	3862 (0.87)		9237 (0.47)
Hospitalization (count, % of positives)	453 (0.11)		1397 (0.02)
Duration, days (med, mean, sd)	5, 7.62 (9.08)		3, 4.78 (7.22)
542 Supplementary Table 4. Demographics for susceptibility modeling cohort

543

	COVID-19 Nasopharyngeal Swab Test Positive		Total Susceptibility modeling cohort (symptom data not required)		
	<i>n</i> = 2,505	<i>n</i> = 16,830	<i>n</i> = 19,335		
Age					
Median, mean (sd)	48, 47.96 (14.68)	53, 52.93 (15.5)	53, 52.29 (15.49)		
Bins (Counts, %)					
18-30	350 (0.14)	1404 (0.08)	1754 (0.09)		
31-40	531 (0.21)	2882 (0.17)	3413 (0.18)		
41-50	511 (0.2)	3073 (0.18)	3584 (0.19)		
51-60	580 (0.23)	3478 (0.21)	4058 (0.21)		
61-70	365 (0.15)	3548 (0.21)	3913 (0.20)		
71-90	168 (0.07)	2445 (0.15)	2613 (0.14)		
Genetic Sex (counts, %)					
Female	1646 (0.66)	11688 (0.69)	13334 (0.69)		
Male	859 (0.34)	5142 (0.31)	6001 (0.31)		
Genetic Ancestry Continental Groupings					
Admixed African-European ancestry	130 (0.05)	730 (0.04)	860 (0.04)		
Admixed Amerindian ancestry	287 (0.11)	1319 (0.08)	1606 (0.08)		
European ancestry	1633 (0.65)	11886 (0.71)	13519 (0.70)		
Other ancestry	455 (0.18)	2885 (0.17)	3350 (0.17)		
Pre-existing health conditions (any)	1131 (0.45)	9168 (0.54)	10299 (0.53)		
BMI (med, mean, sd)					
Total	28.7, 29.95 (7.16)	28.52, 29.88 (6.99)	28.73, 30.02 (7.08)		
Underweight (count, %)	<100	111	135		
Healthy (count, %)	629	4051	4680		
Overweight (count, %)	759	5433	6192		
Obese (count, %)	1069	7012	8081		
Flu					
Shot (yes)	1617 (0.65)	12029 (0.71)	13646 (0.71)		
Test Dx (yes)	125 (0.05)	761 (0.05)	886 (0.05)		
Symptoms (tested pos.)					
General, yes (count, % of pos.)	2254 (0.9)	-	2905 (0.45)		
Hospitalization (count, % of positives)	260 (0.11)	-	292 (0.09)		
Duration, days (med, mean, sd)	5, 6.68 (8.46)	-	4.5, 6.42 (8.08)		

546 Supplementary Table 5. Demographics for severity modeling cohort

547

	COVID-19 Nasopharyngeal Swab Test Positive
	<i>n</i> = 3,585
Age	
Median, mean (sd)	49, 48.62 (14.68)
Bins (Counts, %)	
18-30	463 (0.13)
31-40	725 (0.2)
41-50	748 (0.21)
51-60	832 (0.23)
61-70	555 (0.15)
71-90	262 (0.07)
Genetic Sex (counts, %)	
Female	2303 (0.64)
Male	1282 (0.36)
Genetic Ancestry Continental Groupings	
Admixed African-European ancestry	203 (0.06)
Admixed Amerindian ancestry	397 (0.11)
European ancestry	2317 (0.65)
Other ancestry	668 (0.19)
Pre-existing health conditions (any)	1666 (0.46)
BMI (med, mean, sd)	28.67, 29.83 (7.03)
Underweight (count, %)	<100
Healthy (count, %)	884
Overweight (count, %)	1128
Obese (count, %)	1498
Flu	
Shot (yes)	2293 (0.64)
Test Dx (yes)	174 (0.05)
Symptoms (tested pos.)	
General, yes (count, % of pos.)	3236 (0.9)
Hospitalization (count, % of positives)	391 (0.11)
Duration, days (med, mean, sd)	5, 7.34 (8.73)

550 Supplementary Table 6. Demographics for susceptibility models with symptoms

	Susceptibility modeling cohort (with symptom data)
	<i>n</i> = 4,094
Age	
Median, mean (sd)	58, 55.7 (15.82)
Bins (Counts, %)	
18-30	293 (0.07)
31-40	567 (0.14)
41-50	641 (0.16)
51-60	795 (0.19)
61-70	982 (0.24)
71-90	816 (0.20)
Genetic Sex (counts, %)	
Female	2744 (0.67)
Male	1350 (0.33)
Genetic Ancestry Continental Groupings	
Admixed African-European ancestry	172 (0.04)
Admixed Amerindian ancestry	298 (0.07)
European ancestry	2927 (0.72)
Other ancestry	666 (0.16)
Pre-existing health conditions (any)	2205 (0.54)
BMI (med, mean, sd)	28.59, 29.8 (6.84)
Underweight (count, %)	<100
Healthy (count, %)	1007
Overweight (count, %)	1335
Obese (count, %)	1662
Flu	
Shot (yes)	2935 (0.72)
Test Dx (yes)	160 (0.04)
Symptoms (tested pos.)	
General, yes (count, % of pos.)	1037 (0.25)
Hospitalization (count, % of positives)	<100
Duration, days (med, mean, sd)	5, 7.53 (10.11)

553 Supplementary Table 7. Unadjusted risk factor odds ratios for COVID-19 susceptibility

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.51	(1.26, 1.81)	0.4108	0.0563	3.05E-13	1.28E-11
Ages 30-49	1.10	(0.97, 1.24)	0.0944	0.0377	1.22E-02	5.14E-01
Ages 50-64	1.00		0		nan	nan
Ages 65+	0.68	(0.59, 0.79)	-0.3819	0.0454	0.00E+00	0.00E+00
GENETIC ANCESTRY						
Admixed African-European	1.48	(1.18, 1.85)	0.3925	0.0694	1.57E-08	6.58E-07
European	1.00		0		nan	nan
Admixed Amerindian	1.49	(1.26, 1.77)	0.3995	0.0523	2.10E-14	8.82E-13
Other	1.21	(1.06, 1.38)	0.188	0.041	4.62E-06	1.94E-04
EXPOSURE						
Any	8.72	(7.42, 10.26)	2.1659	0.0501	0.00E+00	0.00E+00
Biological relative tested positive	5.77	(4.99, 6.68)	1.7529	0.045	0.00E+00	0.00E+00
Directly exposed to someone who tested positive	6.94	(6.02, 7.99)	1.9366	0.0438	0.00E+00	0.00E+00
Healthcare worker directly exposed	1.44	(1.26, 1.65)	0.367	0.0408	2.31E-19	9.69E-18
Household member tested positive	26.03	(22.26, 30.43)	3.2591	0.0482	0.00E+00	0.00E+00
HEALTH CONDITIONS						
Asthma	0.81	(0.71, 0.94)	-0.2046	0.0446	4.55E-06	1.91E-04
COPD (Chronic Obstructive Pulmonary Disease)	0.58	(0.41, 0.82)	-0.5374	0.1057	3.72E-07	1.56E-05
Cancer treated in the past year	0.53	(0.36, 0.80)	-0.6283	0.1237	3.80E-07	1.59E-05
Cardiovascular disease	0.71	(0.56, 0.91)	-0.3383	0.0762	9.12E-06	3.83E-04
Chronic kidney disease	0.54	(0.33, 0.87)	-0.6241	0.148	2.48E-05	1.04E-03
Diabetes	0.86	(0.71, 1.03)	-0.1547	0.0561	5.79E-03	2.43E-01
Hypertension	0.78	(0.68, 0.89)	-0.2522	0.0411	8.08E-10	3.40E-08
Other	0.91	(0.73, 1.13)	-0.0939	0.0675	1.64E-01	1.00E+00
Other autoimmune disease	0.77	(0.65, 0.92)	-0.2571	0.054	1.95E-06	8.20E-05
Other immunodeficiency disorder	0.77	(0.53, 1.14)	-0.2552	0.1194	3.25E-02	1.00E+00
Other lung condition	0.59	(0.42, 0.82)	-0.5355	0.1037	2.45E-07	1.03E-05

Any	0.69	(0.62, 0.77)	-0.3667	0.0336	0.00E+00	0.00E+00
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	0.99	(0.86, 1.13)	-0.0146	0.043	7.35E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.00	(0.83, 1.19)	-0.0042	0.056	9.41E-01	1.00E+00
obesity III (BMI >= 40)	0.97	(0.80, 1.19)	-0.0255	0.0622	6.81E-01	1.00E+00
Not obese	1.00		0		nan	nan
GENETIC SEX						
Female	1.00		0		nan	nan
Male	1.27	(1.14, 1.42)	0.2419	0.0329	1.89E-13	7.95E-12
SYMPTOMS					1	
Abdominal pain	1.01	(0.77, 1.33)	0.0139	0.0841	8.69E-01	1.00E+00
Body aches	1.34	(1.06, 1.69)	0.2945	0.0717	4.04E-05	1.70E-03
Change in taste or smell	7.26	(5.54, 9.50)	1.9819	0.0832	1.62E-125	6.81E-124
Chills	1.37	(1.09, 1.71)	0.3126	0.0697	7.23E-06	3.04E-04
Cough producing phlegm	0.88	(0.69, 1.12)	-0.1318	0.0746	7.74E-02	1.00E+00
Diarrhea	1.22	(0.96, 1.56)	0.2006	0.0745	7.11E-03	2.99E-01
Dry cough	1.12	(0.89, 1.40)	0.109	0.0694	1.16E-01	1.00E+00
Feeling tired or fatigue	1.41	(1.05, 1.89)	0.343	0.0901	1.41E-04	5.91E-03
Fever	1.60	(1.28, 2.01)	0.4715	0.0701	1.74E-11	7.30E-10
Headache	1.12	(0.88, 1.41)	0.1098	0.0728	1.32E-01	1.00E+00
Nasal congestion	0.74	(0.59, 0.92)	-0.3072	0.0696	1.01E-05	4.24E-04
Nausea or vomiting	0.99	(0.75, 1.32)	-0.0055	0.0867	9.50E-01	1.00E+00
Runny nose	0.59	(0.47, 0.75)	-0.5245	0.0725	4.49E-13	1.89E-11
Shortness of breath	1.14	(0.91, 1.44)	0.1343	0.0705	5.67E-02	1.00E+00
Sore throat	0.49	(0.39, 0.62)	-0.7052	0.0717	8.10E-23	0.00E+00

555

556 Unadjusted odds ratios for a positive COVID-19 test were calculated among survey participants 557 reporting a test result (positive or negative) based on the self-reported response to the following 558 question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" 559 The following groups served as reference populations for the odds ratio calculations: European 560 genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese 561 (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among 562 symptomatic customers only (Methods).

563 Supplementary Table 8. Risk factors odds ratios for COVID-19 susceptibility, adjusted for

564 **exposure questions**

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)	
AGE							
Ages 18-29	1.27	(1.02, 1.57)	0.2364	0.0670	4.22E-04	1.77E-02	
Ages 30-49	0.95	(0.82, 1.10)	-0.0535	0.0451	2.36E-01	1.00E+00	
Ages 50-64	1.00		0.0000		nan	nan	
Ages 65+	0.99	(0.81, 1.21)	-0.0084	0.0610	8.90E-01	1.00E+00	
GENETIC ANCESTRY							
Admixed African-European	1.23	(0.94, 1.62)	0.2084	0.0848	1.40E-02	5.89E-01	
European	1.00		0.0000		nan	nan	
Admixed Amerindian	1.32	(1.08, 1.62)	0.2810	0.0621	6.13E-06	2.57E-04	
Other	1.10	(0.93, 1.29)	0.0923	0.0504	6.73E-02	1.00E+00	
EXPOSURE							
Any	8.72	(7.42, 10.26)	2.1659	0.0501	0.00E+00	0.00E+00	
Biological relative tested positive	5.77	(4.99, 6.68)	1.7529	0.0450	0.00E+00	0.00E+00	
Directly exposed to someone who tested positive	6.94	(6.02, 7.99)	1.9366	0.0438	0.00E+00	0.00E+00	
Healthcare worker directly exposed	1.44	(1.26, 1.65)	0.3670	0.0408	2.31E-19	9.69E-18	
Household member tested positive	26.03	(22.26, 30.43)	3.2591	0.0482	0.00E+00	0.00E+00	
HEALTH CONDITIONS							
Asthma	0.78	(0.66, 0.93)	-0.2450	0.0519	2.37E-06	9.95E-05	
COPD (Chronic Obstructive Pulmonary Disease)	0.85	(0.57, 1.29)	-0.1571	0.1276	2.18E-01	1.00E+00	
Cancer treated in the past year	0.83	(0.51, 1.34)	-0.1884	0.1480	2.03E-01	1.00E+00	
Cardiovascular disease	0.96	(0.71, 1.29)	-0.0436	0.0920	6.36E-01	1.00E+00	
Chronic kidney disease	0.77	(0.43, 1.37)	-0.2656	0.1784	1.37E-01	1.00E+00	
Diabetes	1.09	(0.88, 1.35)	0.0886	0.0657	1.78E-01	1.00E+00	
Hypertension	0.90	(0.77, 1.05)	-0.1034	0.0479	3.08E-02	1.00E+00	
Other	0.97	(0.75, 1.25)	-0.0293	0.0788	7.11E-01	1.00E+00	
Other autoimmune disease	0.82	(0.67, 1.00)	-0.2042	0.0628	1.15E-03	4.85E-02	
Other immunodeficiency disorder	0.69	(0.43, 1.11)	-0.3735	0.1482	1.18E-02	4.94E-01	

Other lung condition	0.66	(0.44, 0.99)	-0.4166	0.1242	7.99E-04	3.36E-02
Any	0.80	(0.70, 0.91)	-0.2243	0.0391	9.55E-09	4.01E-07
OBESITY		1				
obesity I (BMI >= 30 and BMI < 35)	0.99	(0.84, 1.17)	-0.0079	0.0500	8.75E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.04	(0.84, 1.28)	0.0348	0.0647	5.90E-01	1.00E+00
obesity III (BMI >= 40)	0.99	(0.79, 1.26)	-0.0056	0.0719	9.38E-01	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX		l -			1	
Female	1.00		0.0000		nan	nan
Male	1.35	(1.18, 1.54)	0.2989	0.0408	2.46E-13	1.04E-11
SYMPTOMS		h			1	
Abdominal pain	0.96	(0.68, 1.38)	-0.0364	0.1100	7.41E-01	1.00E+00
Body aches	1.27	(0.94, 1.73)	0.2429	0.0934	9.31E-03	3.91E-01
Change in taste or smell	6.43	(4.59, 9.00)	1.8607	0.1039	1.18E-71	4.94E-70
Chills	1.36	(1.01, 1.82)	0.3073	0.0908	7.11E-04	2.99E-02
Cough producing phlegm	0.89	(0.64, 1.22)	-0.1208	0.0981	2.18E-01	1.00E+00
Diarrhea	1.13	(0.83, 1.55)	0.1258	0.0963	1.92E-01	1.00E+00
Dry cough	1.02	(0.76, 1.37)	0.0243	0.0906	7.88E-01	1.00E+00
Feeling tired or fatigue	1.27	(0.87, 1.86)	0.2389	0.1181	4.31E-02	1.00E+00
Fever	1.53	(1.14, 2.06)	0.4276	0.0911	2.67E-06	1.12E-04
Headache	1.01	(0.74, 1.37)	0.0092	0.0951	9.23E-01	1.00E+00
Nasal congestion	0.69	(0.51, 0.92)	-0.3766	0.0909	3.45E-05	1.45E-03
Nausea or vomiting	0.92	(0.64, 1.33)	-0.0808	0.1122	4.71E-01	1.00E+00
Runny nose	0.56	(0.41, 0.76)	-0.5841	0.0954	9.02E-10	3.79E-08
Shortness of breath	1.26	(0.93, 1.70)	0.2286	0.0926	1.35E-02	5.68E-01
Sore throat	0.46	(0.34, 0.63)	-0.7711	0.0940	2.22E-16	9.33E-15

566

Adjusted odds ratios for a positive COVID-19 test were calculated among survey participants reporting a test result (positive or negative) based on the self-reported response to the following

question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?"
 The following groups served as reference populations for the odds ratio calculations: European

571 genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese

572 (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among

573 symptomatic customers only (Methods). Here, odds ratios were adjusted for four known

574 exposures (Y/N if any).

576 Supplementary Table 9. Risk factor odds ratios for COVID-19 susceptibility, adjusted for

577 **exposure**, age, and sex

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.28	(1.03, 1.59)	0.2448	0.0672	2.72E-04	1.14E-02
Ages 30-49	0.94	(0.81, 1.09)	-0.0583	0.0453	1.97E-01	1.00E+00
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.96	(0.79, 1.18)	-0.0372	0.0613	5.44E-01	1.00E+00
GENETIC ANCESTRY						
Admixed African-European	1.23	(0.94, 1.62)	0.2091	0.0852	1.42E-02	5.95E-01
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.27	(1.04, 1.57)	0.2417	0.0636	1.46E-04	6.11E-03
Other	1.09	(0.92, 1.29)	0.0863	0.0509	8.98E-02	1.00E+00
EXPOSURE	l.			l		
Any	8.63	(7.31, 10.19)	2.1555	0.0512	0.00E+00	0.00E+00
Biological relative tested positive	5.68	(4.90, 6.58)	1.7372	0.0455	0.00E+00	0.00E+00
Directly exposed to someone who tested positive	6.71	(5.80, 7.76)	1.9034	0.0451	0.00E+00	0.00E+00
Healthcare worker directly exposed	1.33	(1.16, 1.52)	0.2823	0.0420	1.75E-11	7.34E-10
Household member tested positive	25.09	(21.44, 29.36)	3.2224	0.0485	0.00E+00	0.00E+00
HEALTH CONDITIONS						
Asthma	0.82	(0.69, 0.97)	-0.2045	0.0524	9.47E-05	3.98E-03
COPD (Chronic Obstructive Pulmonary Disease)	0.88	(0.58, 1.34)	-0.1281	0.1290	3.21E-01	1.00E+00
Cancer treated in the past year	0.83	(0.51, 1.34)	-0.1877	0.1488	2.07E-01	1.00E+00
Cardiovascular disease	0.94	(0.69, 1.28)	-0.0598	0.0944	5.27E-01	1.00E+00
Chronic kidney disease	0.78	(0.44, 1.40)	-0.2475	0.1791	1.67E-01	1.00E+00
Diabetes	1.10	(0.88, 1.36)	0.0922	0.0673	1.71E-01	1.00E+00
Hypertension	0.90	(0.76, 1.05)	-0.1097	0.0499	2.80E-02	1.00E+00
Other	0.99	(0.77, 1.28)	-0.0080	0.0790	9.20E-01	1.00E+00
Other autoimmune disease	0.87	(0.71, 1.07)	-0.1382	0.0636	2.97E-02	1.00E+00
Other immunodeficiency disorder	0.69	(0.42, 1.11)	-0.3764	0.1496	1.19E-02	4.99E-01

Other lung condition	0.67	(0.44, 1.00)	-0.4064	0.1248	1.13E-03	4.76E-02
Any	0.81	(0.71, 0.92)	-0.2092	0.0405	2.32E-07	9.76E-06
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	0.99	(0.84, 1.16)	-0.0113	0.0502	8.23E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.04	(0.84, 1.28)	0.0390	0.0649	5.47E-01	1.00E+00
obesity III (BMI >= 40)	1.01	(0.80, 1.28)	0.0097	0.0724	8.94E-01	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	1.36	(1.19, 1.55)	0.3039	0.0409	1.09E-13	4.57E-12
SYMPTOMS						
Abdominal pain	1.00	(0.70, 1.44)	0.0048	0.1108	9.65E-01	1.00E+00
Body aches	1.29	(0.95, 1.74)	0.2508	0.0941	7.72E-03	3.24E-01
Change in taste or smell	6.68	(4.75, 9.39)	1.8991	0.1052	6.77E-73	2.84E-71
Chills	1.35	(1.01, 1.82)	0.3014	0.0912	9.56E-04	4.02E-02
Cough producing phlegm	0.90	(0.65, 1.23)	-0.1098	0.0986	2.65E-01	1.00E+00
Diarrhea	1.16	(0.85, 1.59)	0.1522	0.0970	1.17E-01	1.00E+00
Dry cough	1.05	(0.78, 1.40)	0.0442	0.0912	6.28E-01	1.00E+00
Feeling tired or fatigue	1.35	(0.92, 2.00)	0.3029	0.1202	1.17E-02	4.91E-01
Fever	1.52	(1.13, 2.05)	0.4189	0.0916	4.76E-06	2.00E-04
Headache	1.02	(0.74, 1.40)	0.0218	0.0977	8.24E-01	1.00E+00
Nasal congestion	0.69	(0.52, 0.93)	-0.3651	0.0918	6.93E-05	2.91E-03
Nausea or vomiting	0.96	(0.67, 1.38)	-0.0401	0.1128	7.22E-01	1.00E+00
Runny nose	0.57	(0.42, 0.77)	-0.5690	0.0958	2.83E-09	1.19E-07
Shortness of breath	1.30	(0.96, 1.76)	0.2607	0.0934	5.22E-03	2.19E-01
Sore throat	0.47	(0.34, 0.64)	-0.7609	0.0951	1.33E-15	5.60E-14

579

580 Adjusted odds ratios for a positive COVID-19 test were calculated among survey participants 581 reporting a test result (positive or negative) based on the self-reported response to the following

question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?"
 The following groups served as reference populations for the odds ratio calculations: European

584 genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese

(BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among

586 symptomatic customers only (Methods). Here, odds ratios were adjusted for four known

587 exposures (Y/N if any), age, and genetic sex (Supplementary Table 2 and Methods).

590 Supplementary Table 10. Unadjusted risk factor odds ratios for a known "direct" COVID-

19 exposure

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.80	(1.54, 2.12)	0.5896	0.0519	6.64E-30	1.66E-28
Ages 30-49	1.45	(1.31, 1.60)	0.3725	0.0325	2.00E-30	5.00E-29
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.32	(0.28, 0.37)	-1.1427	0.0437	0.00E+00	0.00E+00
GENETIC ANCESTRY						
Admixed African-European	1.49	(1.23, 1.82)	0.4012	0.0639	3.32E-10	8.31E-09
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.40	(1.21, 1.62)	0.3384	0.0476	1.13E-12	2.82E-11
Other	1.17	(1.05, 1.31)	0.1584	0.0365	1.47E-05	3.67E-04
EXPOSURE						
Biological relative tested positive	4.43	(3.79, 5.18)	1.4888	0.0503	1.39E-192	3.48E-191
Healthcare worker directly exposed	11.53	(10.16, 13.08)	2.4450	0.0408	0.00E+00	0.00E+00
Household member tested positive	22.53	(17.88, 28.38)	3.1148	0.0747	0.00E+00	0.00E+00
HEALTH CONDITIONS						
Asthma	1.02	(0.92, 1.14)	0.0216	0.0353	5.40E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	0.44	(0.33, 0.57)	-0.8297	0.0875	0.00E+00	0.00E+00
Cancer treated in the past year	0.36	(0.26, 0.49)	-1.0310	0.1012	0.00E+00	0.00E+00
Cardiovascular disease	0.50	(0.41, 0.61)	-0.6880	0.0647	0.00E+00	0.00E+00
Chronic kidney disease	0.39	(0.27, 0.57)	-0.9295	0.1182	3.77E-15	9.44E-14
Diabetes	0.63	(0.54, 0.73)	-0.4656	0.0473	0.00E+00	0.00E+00
Hypertension	0.73	(0.66, 0.81)	-0.3181	0.0332	0.00E+00	0.00E+00
Other	0.99	(0.84, 1.18)	-0.0080	0.0556	8.86E-01	1.00E+00
Other autoimmune disease	0.87	(0.76, 0.99)	-0.1421	0.0424	8.06E-04	2.02E-02
Other immunodeficiency disorder	0.87	(0.65, 1.17)	-0.1389	0.0953	1.45E-01	1.00E+00
Other lung condition	0.62	(0.48, 0.78)	-0.4859	0.0778	4.22E-10	1.05E-08
Any	0.71	(0.65, 0.78)	-0.3393	0.0276	0.00E+00	0.00E+00

OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.03	(0.93, 1.15)	0.0338	0.0350	3.35E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.03	(0.90, 1.19)	0.0343	0.0456	4.52E-01	1.00E+00
obesity III (BMI >= 40)	1.10	(0.94, 1.28)	0.0927	0.0499	6.31E-02	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	0.96	(0.87, 1.05)	-0.0443	0.0295	1.33E-01	1.00E+00

594 Unadjusted odds ratios for a known "direct" exposure to COVID-19 were calculated based on 595 the self-reported response to the following question: "Have you been directly exposed to 596 someone who has tested positive for COVID-19?" The following groups served as reference 597 populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 598 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity).

613 Supplementary Table 11. Unadjusted risk factor odds ratios for a household case(s) of

614 **COVID-19**

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.44	(1.15, 1.79)	0.3623	0.0715	4.01E-07	1.00E-05
Ages 30-49	0.98	(0.84, 1.14)	-0.0204	0.0488	6.76E-01	1.00E+00
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.50	(0.41, 0.61)	-0.6882	0.0641	0.00E+00	0.00E+00
GENETIC ANCESTRY					1	
Admixed African-European	1.35	(1.00, 1.81)	0.2971	0.0954	1.84E-03	4.60E-02
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.95	(1.60, 2.37)	0.6686	0.0634	5.56E-26	1.39E-24
Other	1.23	(1.04, 1.47)	0.2107	0.0557	1.56E-04	3.90E-03
EXPOSURE						
Biological relative tested positive	14.32	(12.30, 16.67)	2.6615	0.0491	0.00E+00	0.00E+00
Directly exposed to someone who tested positive	22.53	(17.88, 28.38)	3.1148	0.0747	0.00E+00	0.00E+00
Healthcare worker directly exposed	1.11	(0.94, 1.32)	0.1073	0.0540	4.71E-02	1.00E+00
HEALTH CONDITIONS						
Asthma	0.91	(0.77, 1.07)	-0.0975	0.0549	7.59E-02	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	0.58	(0.38, 0.89)	-0.5405	0.1363	7.31E-05	1.83E-03
Cancer treated in the past year	0.44	(0.26, 0.75)	-0.8217	0.1735	2.19E-06	5.48E-05
Cardiovascular disease	0.68	(0.50, 0.93)	-0.3795	0.0988	1.23E-04	3.07E-03
Chronic kidney disease	0.53	(0.30, 0.97)	-0.6255	0.1911	1.06E-03	2.66E-02
Diabetes	0.89	(0.72, 1.10)	-0.1187	0.0701	9.02E-02	1.00E+00
Hypertension	0.80	(0.69, 0.94)	-0.2182	0.0516	2.31E-05	5.77E-04
Other	0.93	(0.72, 1.21)	-0.0673	0.0845	4.26E-01	1.00E+00
Other autoimmune disease	0.85	(0.69, 1.04)	-0.1684	0.0667	1.16E-02	2.90E-01
Other immunodeficiency disorder	0.87	(0.56, 1.37)	-0.1357	0.1453	3.50E-01	1.00E+00
Other lung condition	0.63	(0.42, 0.94)	-0.4620	0.1292	3.48E-04	8.70E-03
Any	0.74	(0.65, 0.84)	-0.3047	0.0423	5.80E-13	1.45E-11

OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.05	(0.89, 1.23)	0.0460	0.0533	3.88E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.01	(0.81, 1.25)	0.0064	0.0704	9.28E-01	1.00E+00
obesity III (BMI >= 40)	1.04	(0.82, 1.32)	0.0374	0.0769	6.27E-01	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	1.18	(1.03, 1.36)	0.1688	0.0438	1.16E-04	2.89E-03

617 Unadjusted odds ratios for a household case(s) of COVID-19 were calculated based on the self-

618 reported response to the following question: "Has someone in your household tested positive for 619 COVID-19?" The following groups served as reference populations for the odds ratio 620 calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic 621 Ser), and Net Obese (BML < 20, Obesity)

621 Sex), and Not Obese (BMI < 30, Obesity).

635 Supplementary Table 12. Unadjusted risk factor odds ratios for a COVID-19 case(s)

636 amongst close biological relatives (parent, grandparent, child, or sibling)

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINA L)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.48	(1.18, 1.86)	0.3934	0.0730	7.16E-08	1.79E-06
Ages 30-49	1.02	(0.88, 1.19)	0.0222	0.0502	6.59E-01	1.00E+00
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.70	(0.58, 0.85)	-0.3523	0.0605	5.90E-09	1.47E-07
GENETIC ANCESTRY						
Admixed African-European	1.69	(1.28, 2.22)	0.5221	0.0896	5.62E-09	1.41E-07
European	1.00		0.0000		nan	nan
Admixed Amerindian	2.08	(1.71, 2.53)	0.7333	0.0634	5.85E-31	1.46E-29
Other	1.42	(1.20, 1.68)	0.3472	0.0547	2.14E-10	5.34E-09
EXPOSURE						
Directly exposed to someone who tested positive	4.43	(3.79, 5.18)	1.4888	0.0503	1.39E-192	3.48E-191
Healthcare worker directly exposed	1.04	(0.87, 1.23)	0.0384	0.0558	4.91E-01	1.00E+00
Household member tested positive	14.32	(12.30, 16.67)	2.6615	0.0491	0.00E+00	0.00E+00
HEALTH CONDITIONS						
Asthma	0.98	(0.82, 1.16)	-0.0245	0.0547	6.54E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	0.68	(0.46, 1.02)	-0.3791	0.1293	3.37E-03	8.42E-02
Cancer treated in the past year	0.60	(0.37, 0.97)	-0.5105	0.1542	9.33E-04	2.33E-02
Cardiovascular disease	0.77	(0.57, 1.04)	-0.2600	0.0959	6.72E-03	1.68E-01
Chronic kidney disease	0.52	(0.28, 0.95)	-0.6619	0.1977	8.12E-04	2.03E-02
Diabetes	1.04	(0.84, 1.28)	0.0368	0.0677	5.86E-01	1.00E+00
Hypertension	0.88	(0.75, 1.03)	-0.1281	0.0513	1.25E-02	3.12E-01
Other	1.03	(0.80, 1.33)	0.0297	0.0829	7.20E-01	1.00E+00
Other autoimmune disease	0.90	(0.73, 1.10)	-0.1057	0.0663	1.11E-01	1.00E+00
Other immunodeficiency disorder	0.99	(0.65, 1.53)	-0.0065	0.1394	9.63E-01	1.00E+00
Other lung condition	0.96	(0.69, 1.36)	-0.0368	0.1104	7.39E-01	1.00E+00
Any	0.85	(0.74, 0.97)	-0.1668	0.0429	1.02E-04	2.55E-03

OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.03	(0.87, 1.22)	0.0327	0.0541	5.45E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	0.88	(0.70, 1.11)	-0.1292	0.0748	8.41E-02	1.00E+00
obesity III (BMI >= 40)	1.10	(0.87, 1.39)	0.0945	0.0761	2.14E-01	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	0.87	(0.75, 1.00)	-0.1404	0.0462	2.39E-03	5.99E-02

Unadjusted odds ratios for a case(s) of COVID-19 among close biological relatives (grandparent,
parent, child, or sibling) were calculated based on the self-reported response to the following
question: "Have any of your biological relatives tested positive for COVID-19? Select all that
apply." The following groups served as reference populations for the odds ratio calculations:
European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and
Not Obese (BMI < 30, Obesity).

658 Supplementary Table 13. Unadjusted risk factor odds ratios for COVID-19 hospitalization

659

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.42	(0.21, 0.83)	-0.8793	0.2143	4.06E-05	1.71E-03
Ages 30-49	0.54	(0.36, 0.81)	-0.6143	0.1246	8.24E-07	3.46E-05
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	1.70	(1.13, 2.56)	0.5325	0.1263	2.49E-05	1.05E-03
GENETIC ANCESTRY						
Admixed African-European	1.44	(0.78, 2.65)	0.3625	0.1884	5.43E-02	1.00E+00
European	1.00		0.0000		nan	nan
Admixed Amerindian	0.77	(0.44, 1.36)	-0.2579	0.1745	1.39E-01	1.00E+00
Other	0.91	(0.59, 1.40)	-0.0964	0.1335	4.70E-01	1.00E+00
EXPOSURE						
Any	0.74	(0.46, 1.19)	-0.3048	0.1483	3.98E-02	1.00E+00
Biological relative tested positive	1.17	(0.81, 1.69)	0.1550	0.1136	1.73E-01	1.00E+00
Directly exposed to someone who tested positive	0.63	(0.42, 0.96)	-0.4595	0.1279	3.28E-04	1.38E-02
Healthcare worker directly exposed	0.53	(0.34, 0.84)	-0.6317	0.1423	9.09E-06	3.82E-04
Household member tested positive	0.91	(0.65, 1.27)	-0.0971	0.1033	3.47E-01	1.00E+00
HEALTH CONDITIONS						
Asthma	1.42	(0.95, 2.13)	0.3525	0.1249	4.77E-03	2.00E-01
COPD (Chronic Obstructive Pulmonary Disease)	3.48	(1.65, 7.32)	1.2469	0.2296	5.64E-08	2.37E-06
Cancer treated in the past year	3.13	(1.29, 7.57)	1.1396	0.2730	2.99E-05	1.26E-03
Cardiovascular disease	2.82	(1.61, 4.96)	1.0374	0.1740	2.50E-09	1.05E-07
Chronic kidney disease	8.74	(3.44, 22.21)	2.1684	0.2876	4.71E-14	1.98E-12
Diabetes	3.03	(1.98, 4.63)	1.1085	0.1311	2.78E-17	1.17E-15
Hypertension	2.01	(1.41, 2.88)	0.7002	0.1105	2.37E-10	9.96E-09
Other	1.65	(0.93, 2.93)	0.5038	0.1767	4.35E-03	1.83E-01
Other autoimmune disease	1.32	(0.81, 2.17)	0.2811	0.1523	6.49E-02	1.00E+00
Other immunodeficiency disorder	1.98	(0.77, 5.09)	0.6826	0.2915	1.92E-02	8.05E-01
Other lung condition	2.84	(1.32, 6.10)	1.0423	0.2364	1.04E-05	4.35E-04

Any	2.70	(1.90, 3.83)	0.9919	0.1081	4.43E-20	1.86E-18
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.41	(0.94, 2.12)	0.3418	0.1258	6.61E-03	2.78E-01
obesity II (BMI >= 35 and BMI < 40)	1.21	(0.70, 2.09)	0.1883	0.1693	2.66E-01	1.00E+00
obesity III (BMI >= 40)	1.62	(0.93, 2.83)	0.4820	0.1719	5.04E-03	2.12E-01
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	1.27	(0.92, 1.77)	0.2418	0.1015	1.72E-02	7.22E-01
SYMPTOMS					la de la constante de la const	
Abdominal pain	1.76	(1.23, 2.52)	0.5638	0.1112	3.92E-07	1.65E-05
Body aches	1.39	(0.96, 2.02)	0.3309	0.1142	3.75E-03	1.57E-01
Change in taste or smell	0.77	(0.55, 1.07)	-0.2657	0.1039	1.05E-02	4.42E-01
Chills	1.82	(1.29, 2.57)	0.5991	0.1061	1.65E-08	6.92E-07
Cough producing phlegm	1.56	(1.11, 2.20)	0.4474	0.1054	2.19E-05	9.18E-04
Diarrhea	2.12	(1.52, 2.95)	0.7521	0.1021	1.75E-13	7.35E-12
Dry cough	2.59	(1.81, 3.71)	0.9528	0.1104	6.26E-18	2.63E-16
Feeling tired or fatigue	2.54	(1.35, 4.78)	0.9335	0.1949	1.68E-06	7.04E-05
Fever	3.33	(2.26, 4.90)	1.2032	0.1192	5.93E-24	2.49E-22
Headache	0.89	(0.63, 1.26)	-0.1125	0.1063	2.90E-01	1.00E+00
Nasal congestion	0.94	(0.67, 1.31)	-0.0610	0.1030	5.54E-01	1.00E+00
Nausea or vomiting	2.26	(1.58, 3.23)	0.8156	0.1104	1.52E-13	6.39E-12
Runny nose	1.09	(0.76, 1.56)	0.0831	0.1118	4.57E-01	1.00E+00
Shortness of breath	7.52	(4.92, 11.49)	2.0172	0.1309	1.48E-53	6.21E-52
Sore throat	1.04	(0.72, 1.50)	0.0386	0.1127	7.32E-01	1.00E+00

660

661 Unadjusted odds ratios for hospitalization due to COVID-19 infection were calculated among
662 those reporting a positive COVID-19 test result. The following groups served as reference
663 populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages
664 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms
665 odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).

667 Supplementary Table 14. Risk factor odds ratios for COVID-19 hospitalization, adjusted

668 for health conditions, obesity, age, and sex

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.56	(0.26, 1.20)	-0.5815	0.2359	1.37E-02	5.75E-01
Ages 30-49	0.60	(0.39, 0.92)	-0.5110	0.1333	1.26E-04	5.28E-03
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	1.60	(1.02, 2.51)	0.4713	0.1381	6.43E-04	2.70E-02
GENETIC ANCESTRY						
Admixed African-European	1.57	(0.81, 3.03)	0.4513	0.2026	2.59E-02	1.00E+00
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.11	(0.59, 2.07)	0.1035	0.1922	5.90E-01	1.00E+00
Other	0.95	(0.59, 1.54)	-0.0493	0.1490	7.41E-01	1.00E+00
EXPOSURE						
Any	0.81	(0.48, 1.39)	-0.2060	0.1653	2.13E-01	1.00E+00
Biological relative tested positive	1.16	(0.78, 1.74)	0.1498	0.1248	2.30E-01	1.00E+00
Directly exposed to someone who tested positive	0.68	(0.43, 1.07)	-0.3870	0.1397	5.61E-03	2.36E-01
Healthcare worker directly exposed	0.63	(0.38, 1.04)	-0.4685	0.1567	2.79E-03	1.17E-01
Household member tested positive	0.88	(0.62, 1.26)	-0.1245	0.1109	2.62E-01	1.00E+00
HEALTH CONDITIONS						
Asthma	1.42	(0.92, 2.20)	0.3537	0.1343	8.42E-03	3.54E-01
COPD (Chronic Obstructive Pulmonary Disease)	2.25	(0.99, 5.14)	0.8123	0.2542	1.40E-03	5.87E-02
Cancer treated in the past year	1.90	(0.72, 5.04)	0.6422	0.3012	3.30E-02	1.00E+00
Cardiovascular disease	1.67	(0.90, 3.11)	0.5139	0.1914	7.24E-03	3.04E-01
Chronic kidney disease	5.62	(2.10, 15.03)	1.7267	0.3034	1.26E-08	5.30E-07
Diabetes	2.22	(1.39, 3.55)	0.7988	0.1442	3.06E-08	1.28E-06
Hypertension	1.32	(0.88, 1.97)	0.2757	0.1239	2.61E-02	1.00E+00
Other	1.47	(0.80, 2.71)	0.3878	0.1875	3.86E-02	1.00E+00
Other autoimmune disease	1.41	(0.83, 2.40)	0.3461	0.1635	3.42E-02	1.00E+00
Other immunodeficiency disorder	1.83	(0.68, 4.93)	0.6032	0.3062	4.88E-02	1.00E+00

Other lung condition	1.87	(0.83, 4.22)	0.6242	0.2514	1.30E-02	5.47E-01
Any	2.08	(1.42, 3.04)	0.7333	0.1172	3.93E-10	1.65E-08
OBESITY					1	
obesity I (BMI >= 30 and BMI < 35)	1.19	(0.77, 1.82)	0.1707	0.1323	1.97E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.13	(0.64, 2.00)	0.1249	0.1750	4.75E-01	1.00E+00
obesity III (BMI >= 40)	1.59	(0.88, 2.87)	0.4631	0.1821	1.10E-02	4.62E-01
Not obese	1.00		0.0000		nan	nan
GENETIC SEX					1	
Female	1.00		0.0000		nan	nan
Male	1.22	(0.85, 1.74)	0.1960	0.1103	7.57E-02	1.00E+00
SYMPTOMS					1	
Abdominal pain	1.66	(1.12, 2.46)	0.5086	0.1214	2.81E-05	1.18E-03
Body aches	1.44	(0.96, 2.15)	0.3646	0.1240	3.27E-03	1.37E-01
Change in taste or smell	0.89	(0.62, 1.29)	-0.1159	0.1139	3.09E-01	1.00E+00
Chills	1.94	(1.33, 2.82)	0.6609	0.1156	1.07E-08	4.51E-07
Cough producing phlegm	1.41	(0.97, 2.05)	0.3470	0.1150	2.54E-03	1.07E-01
Diarrhea	2.23	(1.55, 3.20)	0.8014	0.1120	8.21E-13	3.45E-11
Dry cough	2.49	(1.69, 3.67)	0.9114	0.1196	2.55E-14	1.07E-12
Feeling tired or fatigue	2.81	(1.38, 5.74)	1.0333	0.2203	2.73E-06	1.15E-04
Fever	3.49	(2.29, 5.34)	1.2510	0.1309	1.24E-21	5.19E-20
Headache	1.05	(0.72, 1.54)	0.0487	0.1180	6.80E-01	1.00E+00
Nasal congestion	0.93	(0.65, 1.34)	-0.0698	0.1122	5.34E-01	1.00E+00
Nausea or vomiting	2.41	(1.62, 3.59)	0.8801	0.1230	8.38E-13	3.52E-11
Runny nose	0.93	(0.62, 1.39)	-0.0710	0.1232	5.65E-01	1.00E+00
Shortness of breath	8.20	(5.14, 13.08)	2.1042	0.1440	2.37E-48	9.96E-47
Sore throat	1.11	(0.75, 1.66)	0.1074	0.1224	3.80E-01	1.00E+00

670

Adjusted odds ratios for hospitalization due to COVID-19 infection were calculated among those reporting a positive COVID-19 test result. The following groups served as reference populations

for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age),

Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms odds ratios

675 were calculated in a binary fashion among symptomatic customers only (Methods). Here, odds

ratios were adjusted for age, sex, comorbitidies (Y/N if any), and obesity (Y/N if BMI > 30,

677 Methods).

679 Supplementary Table 15. Unadjusted risk factor odds ratios for progression of COVID-19

680 to a critical case.

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.35	(0.13, 0.95)	-1.0599	0.3114	6.64E-04	2.79E-02
Ages 30-49	0.55	(0.32, 0.94)	-0.5983	0.1652	2.92E-04	1.23E-02
Ages 50-64	1		0		nan	nan
Ages 65+	1.65	(0.97, 2.80)	0.5001	0.1632	2.19E-03	9.18E-02
GENETIC ANCESTRY						
Admixed African-European	2.07	(1.03, 4.17)	0.7269	0.2166	7.91E-04	3.32E-02
European	1		0		nan	nan
Admixed Amerindian	0.75	(0.35, 1.62)	-0.2871	0.2377	2.27E-01	1.00E+00
Other	0.82	(0.45, 1.49)	-0.2044	0.1853	2.70E-01	1.00E+00
EXPOSURE						
Any	0.77	(0.40, 1.45)	-0.2675	0.1981	1.77E-01	1.00E+00
Biological relative tested positive	1.15	(0.70, 1.86)	0.1356	0.1502	3.67E-01	1.00E+00
Directly exposed to someone who tested positive	0.59	(0.34, 1.01)	-0.5348	0.1691	1.56E-03	6.55E-02
Healthcare worker directly exposed	0.53	(0.29, 0.99)	-0.6277	0.1912	1.03E-03	4.31E-02
Household member tested positive	1.00	(0.64, 1.55)	-0.0001	0.1353	1.00E+00	1.00E+00
HEALTH CONDITIONS						
Asthma	1.26	(0.74, 2.17)	0.235	0.1672	1.60E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	3.76	(1.57, 9.02)	1.3257	0.2696	8.79E-07	3.69E-05
Cancer treated in the past year	2.07	(0.60, 7.12)	0.7266	0.3814	5.68E-02	1.00E+00
Cardiovascular disease	2.44	(1.17, 5.05)	0.8906	0.2251	7.60E-05	3.19E-03
Chronic kidney disease	8.00	(2.92, 21.91)	2.0794	0.3109	2.26E-11	9.47E-10
Diabetes	3.14	(1.85, 5.32)	1.1431	0.1629	2.29E-12	9.61E-11
Hypertension	2.06	(1.30, 3.27)	0.7214	0.1425	4.15E-07	1.74E-05
Other	1.07	(0.45, 2.54)	0.0649	0.2674	8.08E-01	1.00E+00
Other autoimmune disease	1.35	(0.71, 2.55)	0.2973	0.1973	1.32E-01	1.00E+00
Other immunodeficiency disorder	1.81	(0.53, 6.16)	0.5907	0.3788	1.19E-01	1.00E+00

Other lung condition	3.29	(1.35, 8.00)	1.1909	0.274	1.39E-05	5.82E-04
Any	2.85	(1.78, 4.57)	1.0485	0.1452	5.22E-13	2.19E-11
OBESITY					1	
obesity I (BMI >= 30 and BMI < 35)	1.31	(0.76, 2.27)	0.2714	0.1696	1.09E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.16	(0.56, 2.43)	0.1525	0.2275	5.03E-01	1.00E+00
obesity III (BMI >= 40)	2.06	(1.05, 4.02)	0.7211	0.2071	4.98E-04	2.09E-02
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.54	(1.00, 2.37)	0.4342	0.1325	1.05E-03	4.42E-02
SYMPTOMS						
Abdominal pain	1.95	(1.23, 3.08)	0.666	0.1413	2.45E-06	1.03E-04
Body aches	1.58	(0.95, 2.60)	0.4547	0.1546	3.27E-03	1.37E-01
Change in taste or smell	0.79	(0.51, 1.23)	-0.2319	0.1358	8.79E-02	1.00E+00
Chills	2.04	(1.28, 3.23)	0.7106	0.1423	5.96E-07	2.50E-05
Cough producing phlegm	1.83	(1.18, 2.84)	0.6063	0.1351	7.24E-06	3.04E-04
Diarrhea	2.48	(1.61, 3.84)	0.9102	0.1339	1.08E-11	4.53E-10
Dry cough	2.67	(1.66, 4.31)	0.9836	0.1474	2.49E-11	1.04E-09
Feeling tired or fatigue	2.55	(1.09, 5.97)	0.9344	0.2628	3.77E-04	1.58E-02
Fever	3.52	(2.08, 5.96)	1.2595	0.1622	8.00E-15	3.36E-13
Headache	0.97	(0.61, 1.52)	-0.0356	0.1402	8.00E-01	1.00E+00
Nasal congestion	1.06	(0.69, 1.64)	0.0592	0.1337	6.58E-01	1.00E+00
Nausea or vomiting	2.27	(1.44, 3.60)	0.8217	0.1415	6.30E-09	2.64E-07
Runny nose	1.31	(0.83, 2.07)	0.2696	0.1415	5.68E-02	1.00E+00
Shortness of breath	11.55	(5.91, 22.59)	2.4466	0.2069	2.93E-32	1.23E-30
Sore throat	1.45	(0.92, 2.29)	0.374	0.1396	7.40E-03	3.11E-01

682

Unadjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening
illness were calculated among those reporting a positive COVID-19 test result. The following
groups served as reference populations for the odds ratio calculations: European genetic ancestry
(Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30,
Obesity). Note that symptoms odds ratios were calculated in a binary fashion among
symptomatic customers only (Methods).

- 690 Supplementary Table 16. Risk factor odds ratios for progression of COVID-19 to a critical
- 691 case, adjusted for health conditions, obesity, age, and sex.
- 692

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE					1	
Ages 18-29	0.46	(0.15, 1.45)	-0.7675	0.3506	2.86E-02	1.00E+00
Ages 30-49	0.67	(0.38, 1.17)	-0.4033	0.1735	2.01E-02	8.45E-01
Ages 50-64	1		0		nan	nan
Ages 65+	1.51	(0.85, 2.69)	0.41	0.1785	2.16E-02	9.07E-01
GENETIC ANCESTRY					1	
Admixed African-European	2.34	(1.11, 4.95)	0.8516	0.2308	2.25E-04	9.43E-03
European	1		0		nan	nan
Admixed Amerindian	1.12	(0.49, 2.56)	0.1145	0.2548	6.53E-01	1.00E+00
Other	0.85	(0.44, 1.65)	-0.164	0.206	4.26E-01	1.00E+00
EXPOSURE						
Any	0.83	(0.41, 1.67)	-0.1862	0.2163	3.89E-01	1.00E+00
Biological relative tested positive	1.23	(0.73, 2.08)	0.2104	0.1609	1.91E-01	1.00E+00
Directly exposed to someone who tested positive	0.62	(0.34, 1.13)	-0.4747	0.183	9.49E-03	3.98E-01
Healthcare worker directly exposed	0.62	(0.31, 1.24)	-0.4703	0.2116	2.63E-02	1.00E+00
Household member tested positive	1.01	(0.63, 1.60)	0.0068	0.1434	9.62E-01	1.00E+00
HEALTH CONDITIONS						
Asthma	1.24	(0.69, 2.22)	0.2124	0.1806	2.40E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	2.39	(0.90, 6.36)	0.8704	0.302	3.95E-03	1.66E-01
Cancer treated in the past year	1.08	(0.26, 4.55)	0.0784	0.4429	8.59E-01	1.00E+00
Cardiovascular disease	1.42	(0.64, 3.15)	0.3485	0.2469	1.58E-01	1.00E+00
Chronic kidney disease	4.88	(1.67, 14.30)	1.586	0.3314	1.70E-06	7.13E-05
Diabetes	2.16	(1.20, 3.89)	0.7699	0.1816	2.23E-05	9.38E-04
Hypertension	1.34	(0.80, 2.24)	0.2903	0.1599	6.95E-02	1.00E+00
Other	1.19	(0.49, 2.88)	0.1765	0.2714	5.16E-01	1.00E+00
Other autoimmune disease	1.55	(0.78, 3.06)	0.4368	0.2105	3.80E-02	1.00E+00
Other immunodeficiency disorder	1.82	(0.52, 6.31)	0.5962	0.3844	1.21E-01	1.00E+00

Other lung condition	2.09	(0.80, 5.47)	0.7376	0.2965	1.29E-02	5.40E-01
Any	2.22	(1.33, 3.69)	0.7959	0.157	4.00E-07	1.68E-05
OBESITY					1	
obesity I (BMI >= 30 and BMI < 35)	1.09	(0.62, 1.93)	0.0882	0.1761	6.17E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.06	(0.50, 2.26)	0.0605	0.2334	7.96E-01	1.00E+00
obesity III (BMI >= 40)	1.95	(0.96, 3.98)	0.6695	0.2196	2.29E-03	9.64E-02
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.5	(0.95, 2.37)	0.4041	0.142	4.42E-03	1.85E-01
SYMPTOMS					1	
Abdominal pain	2.03	(1.24, 3.32)	0.7095	0.1514	2.77E-06	1.16E-04
Body aches	1.88	(1.08, 3.27)	0.6321	0.1707	2.13E-04	8.95E-03
Change in taste or smell	1.03	(0.63, 1.66)	0.025	0.1485	8.66E-01	1.00E+00
Chills	2.22	(1.35, 3.66)	0.7975	0.1542	2.31E-07	9.70E-06
Cough producing phlegm	1.69	(1.05, 2.70)	0.5233	0.1452	3.14E-04	1.32E-02
Diarrhea	2.74	(1.71, 4.39)	1.0077	0.1457	4.58E-12	1.92E-10
Dry cough	2.73	(1.62, 4.59)	1.0041	0.1601	3.60E-10	1.51E-08
Feeling tired or fatigue	2.86	(1.10, 7.40)	1.05	0.2938	3.51E-04	1.48E-02
Fever	3.34	(1.91, 5.85)	1.2074	0.1726	2.65E-12	1.11E-10
Headache	1.18	(0.72, 1.95)	0.1678	0.1537	2.75E-01	1.00E+00
Nasal congestion	1.12	(0.70, 1.78)	0.1106	0.1435	4.41E-01	1.00E+00
Nausea or vomiting	2.72	(1.65, 4.49)	0.9997	0.1547	1.03E-10	4.31E-09
Runny nose	1.19	(0.72, 1.95)	0.1704	0.153	2.65E-01	1.00E+00
Shortness of breath	12.87	(6.18, 26.81)	2.5549	0.2265	1.62E-29	6.79E-28
Sore throat	1.65	(1.01, 2.68)	0.4991	0.1503	9.01E-04	3.79E-02

693

Adjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening illness were calculated among those reporting a positive COVID-19 test result. The following groups served as reference populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among symptomatic customers only (Methods). Here, odds ratios were adjusted for age, sex, comorbitidies (Y/N if any), and obesity (Y/N if BMI > 30, Methods).

701 Supplementary Table 17. Unadjusted risk factor odds ratios for COVID-19 susceptibility

702 (training dataset)

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.6	(1.21, 2.11)	0.4693	0.0857	4.42E-08	1.86E-06
Ages 30-49	1.11	(0.92, 1.34)	0.105	0.0584	7.22E-02	1.00E+00
Ages 50-64	1		0		nan	nan
Ages 65+	0.49	(0.38, 0.63)	-0.7051	0.077	0.00E+00	0.00E+00
GENETIC ANCESTRY					1	
Admixed African-European	1.24	(0.85, 1.81)	0.2158	0.1168	6.47E-02	1.00E+00
European	1		0		nan	nan
Admixed Amerindian	1.59	(1.22, 2.07)	0.462	0.0814	1.36E-08	5.73E-07
Other	1.16	(0.94, 1.44)	0.1516	0.0665	2.27E-02	9.52E-01
EXPOSURE						
Any	9.49	(7.65, 11.77)	2.2503	0.0665	4.79E-251	2.01E-249
Biological relative tested positive	5.74	(4.66, 7.07)	1.7467	0.0644	4.71E-162	1.98E-160
Directly exposed to someone who tested positive	7.63	(6.33, 9.19)	2.0317	0.0576	4.44E-272	1.87E-270
Healthcare worker directly exposed	1.56	(1.29, 1.87)	0.4417	0.0576	1.78E-14	7.47E-13
Household member tested positive	24.28	(19.62, 30.03)	3.1896	0.0657	0.00E+00	0.00E+00
PRE-EXISTING CONDITION						
Asthma	0.81	(0.65, 1.00)	-0.2166	0.0677	1.37E-03	5.75E-02
COPD (Chronic Obstructive Pulmonary Disease)	0.54	(0.31, 0.93)	-0.6217	0.1684	2.22E-04	9.32E-03
Cancer treated in the past year	0.57	(0.32, 1.00)	-0.564	0.1731	1.12E-03	4.71E-02
Cardiovascular disease	0.74	(0.51, 1.06)	-0.3014	0.1122	7.26E-03	3.05E-01
Chronic kidney disease	0.55	(0.28, 1.10)	-0.5938	0.2139	5.49E-03	2.31E-01
Diabetes	0.9	(0.69, 1.17)	-0.105	0.0816	1.98E-01	1.00E+00
Hypertension	0.76	(0.62, 0.93)	-0.2728	0.061	7.64E-06	3.21E-04
Other	0.93	(0.66, 1.31)	-0.0726	0.1049	4.89E-01	1.00E+00
Other autoimmune disease	0.8	(0.61, 1.04)	-0.2241	0.081	5.65E-03	2.37E-01
Other immunodeficiency disorder	0.77	(0.42, 1.40)	-0.2669	0.1854	1.50E-01	1.00E+00
Other lung condition	0.64	(0.39, 1.03)	-0.4524	0.1502	2.59E-03	1.09E-01

Any	0.67	(0.57, 0.79)	-0.3983	0.0498	1.33E-15	5.60E-14
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.02	(0.83, 1.25)	0.0212	0.0628	7.35E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.15	(0.94, 1.41)	0.1376	0.0626	2.81E-02	1.00E+00
obesity III (BMI >= 40)	1.13	(0.85, 1.50)	0.12	0.0874	1.70E-01	1.00E+00
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.16	(0.98, 1.37)	0.1459	0.0525	5.43E-03	2.28E-01
SYMPTOMS						
Abdominal pain	0.97	(0.64, 1.48)	-0.0303	0.1303	8.16E-01	1.00E+00
Body aches	1.56	(1.09, 2.23)	0.4461	0.1104	5.34E-05	2.24E-03
Change in taste or smell	7.02	(4.67, 10.56)	1.9493	0.1257	2.96E-54	1.24E-52
Chills	1.38	(0.97, 1.96)	0.3211	0.1085	3.08E-03	1.29E-01
Cough producing phlegm	0.93	(0.64, 1.37)	-0.0685	0.1178	5.61E-01	1.00E+00
Diarrhea	1.18	(0.81, 1.72)	0.1672	0.1158	1.49E-01	1.00E+00
Dry cough	1.29	(0.91, 1.84)	0.2578	0.1082	1.72E-02	7.21E-01
Feeling tired or fatigue	1.54	(0.99, 2.42)	0.4341	0.1381	1.67E-03	7.03E-02
Fever	1.54	(1.08, 2.19)	0.4295	0.1088	7.84E-05	3.29E-03
Headache	1.39	(0.97, 2.00)	0.33	0.1118	3.17E-03	1.33E-01
Nasal congestion	0.85	(0.60, 1.21)	-0.1632	0.1081	1.31E-01	1.00E+00
Nausea or vomiting	0.82	(0.53, 1.26)	-0.1979	0.1327	1.36E-01	1.00E+00
Runny nose	0.59	(0.41, 0.86)	-0.5246	0.1137	3.92E-06	1.65E-04
Shortness of breath	1.25	(0.87, 1.79)	0.2219	0.1106	4.48E-02	1.00E+00
Sore throat	0.48	(0.34, 0.69)	-0.7286	0.1117	6.84E-11	2.87E-09

703

Unadjusted odds ratios for a positive COVID-19 test were calculated among survey participants
reporting a test result (positive or negative). The following groups served as reference
populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages
50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms
odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).

710 Supplementary Table 18. Unadjusted risk factor odds ratios for COVID-19 hospitalization

711 (training dataset)

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.53	(0.20, 1.37)	-0.6395	0.2951	3.02E-02	1.00E+00
Ages 30-49	0.5	(0.27, 0.92)	-0.6907	0.1879	2.37E-04	9.95E-03
Ages 50-64	1		0		nan	nan
Ages 65+	1.64	(0.87, 3.08)	0.4956	0.1943	1.07E-02	4.51E-01
GENETIC ANCESTRY					1	
Admixed African-European	1.19	(0.43, 3.28)	0.176	0.3121	5.73E-01	1.00E+00
European	1		0		nan	nan
Admixed Amerindian	0.77	(0.32, 1.86)	-0.2551	0.2703	3.45E-01	1.00E+00
Other	0.69	(0.34, 1.39)	-0.3752	0.2169	8.37E-02	1.00E+00
EXPOSURE					1	
Any	0.69	(0.34, 1.39)	-0.3732	0.2174	8.61E-02	1.00E+00
Biological relative tested positive	1.06	(0.60, 1.88)	0.0572	0.1772	7.47E-01	1.00E+00
Directly exposed to someone who tested positive	0.54	(0.29, 0.98)	-0.6207	0.1867	8.86E-04	3.72E-02
Healthcare worker directly exposed	0.57	(0.29, 1.10)	-0.5698	0.2042	5.26E-03	2.21E-01
Household member tested positive	0.88	(0.53, 1.45)	-0.1332	0.1551	3.90E-01	1.00E+00
HEALTH CONDITIONS		1			1	
Asthma	1.17	(0.62, 2.19)	0.1555	0.1944	4.24E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	2.95	(0.82, 10.67)	1.083	0.3962	6.27E-03	2.63E-01
Cancer treated in the past year	3.21	(0.88, 11.78)	1.1677	0.4006	3.56E-03	1.49E-01
Cardiovascular disease	2.73	(1.18, 6.28)	1.0036	0.2573	9.62E-05	4.04E-03
Chronic kidney disease	10.82	(2.86, 40.90)	2.3812	0.4103	6.49E-09	2.73E-07
Diabetes	3.21	(1.70, 6.06)	1.1676	0.1957	2.44E-09	1.02E-07
Hypertension	1.68	(0.98, 2.88)	0.5172	0.1664	1.88E-03	7.91E-02
Other	1.63	(0.74, 3.63)	0.4906	0.2463	4.64E-02	1.00E+00
Other autoimmune disease	1.21	(0.58, 2.54)	0.1914	0.2288	4.03E-01	1.00E+00
Other immunodeficiency disorder	0.77	(0.11, 5.53)	-0.2655	0.6094	6.63E-01	1.00E+00

Other lung condition	1.8	(0.50, 6.55)	0.5883	0.3983	1.40E-01	1.00E+00
Any	2.36	(1.41, 3.93)	0.8574	0.1575	5.26E-08	2.21E-06
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.32	(0.74, 2.34)	0.2765	0.1771	1.19E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.08	(0.56, 2.06)	0.0753	0.2001	7.07E-01	1.00E+00
obesity III (BMI >= 40)	1.42	(0.62, 3.26)	0.3505	0.2566	1.72E-01	1.00E+00
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.29	(0.79, 2.12)	0.2584	0.1525	9.02E-02	1.00E+00
SYMPTOMS						
Abdominal pain	1.79	(1.04, 3.10)	0.5841	0.1686	5.33E-04	2.24E-02
Body aches	1.6	(0.90, 2.83)	0.4695	0.1765	7.80E-03	3.28E-01
Change in taste or smell	0.83	(0.50, 1.38)	-0.189	0.1582	2.32E-01	1.00E+00
Chills	2.18	(1.29, 3.71)	0.7814	0.1632	1.68E-06	7.07E-05
Cough producing phlegm	1.51	(0.90, 2.53)	0.4096	0.1596	1.03E-02	4.31E-01
Diarrhea	2.04	(1.24, 3.36)	0.7114	0.154	3.87E-06	1.62E-04
Dry cough	2.5	(1.47, 4.28)	0.9179	0.1653	2.80E-08	1.18E-06
Feeling tired or fatigue	4.47	(1.35, 14.73)	1.4965	0.3681	4.79E-05	2.01E-03
Fever	3.06	(1.72, 5.44)	1.1178	0.178	3.36E-10	1.41E-08
Headache	0.87	(0.52, 1.47)	-0.1351	0.16	3.99E-01	1.00E+00
Nasal congestion	0.73	(0.44, 1.23)	-0.3139	0.1595	4.90E-02	1.00E+00
Nausea or vomiting	2.48	(1.45, 4.23)	0.9068	0.1653	4.13E-08	1.74E-06
Runny nose	0.87	(0.49, 1.55)	-0.1355	0.1777	4.46E-01	1.00E+00
Shortness of breath	6.4	(3.49, 11.73)	1.8558	0.187	3.34E-23	1.40E-21
Sore throat	1.03	(0.59, 1.80)	0.0332	0.1717	8.47E-01	1.00E+00

713

714 Unadjusted odds ratios for hospitalization due to COVID-19 infection were calculated among 715 those reporting a positive COVID-19 test result. The following groups served as reference

populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages

717 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms

odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).

720 Supplementary Table 19. Unadjusted risk factor odds ratios for progression of COVID-19

721 to a critical case (training dataset)

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.48	(0.12, 1.84)	-0.7444	0.4175	7.46E-02	1.00E+00
Ages 30-49	0.61	(0.28, 1.33)	-0.4935	0.2408	4.04E-02	1.00E+00
Ages 50-64	1		0		nan	nan
Ages 65+	1.32	(0.56, 3.12)	0.2779	0.2651	2.95E-01	1.00E+00
GENETIC ANCESTRY						
Admixed African-European	2.2	(0.72, 6.73)	0.7892	0.3445	2.20E-02	9.24E-01
European	1		0		nan	nan
Admixed Amerindian	1.08	(0.36, 3.21)	0.0779	0.3354	8.16E-01	1.00E+00
Other	0.84	(0.34, 2.13)	-0.1692	0.2852	5.53E-01	1.00E+00
EXPOSURE					1	
Any	0.67	(0.26, 1.72)	-0.3951	0.2884	1.71E-01	1.00E+00
Biological relative tested positive	1.18	(0.56, 2.50)	0.1677	0.2304	4.67E-01	1.00E+00
Directly exposed to someone who tested positive	0.46	(0.20, 1.03)	-0.7835	0.2502	1.74E-03	7.31E-02
Healthcare worker directly exposed	0.61	(0.25, 1.47)	-0.4938	0.2711	6.85E-02	1.00E+00
Household member tested positive	0.99	(0.51, 1.93)	-0.0064	0.2055	9.75E-01	1.00E+00
PRE-EXISTING CONDITION						
Asthma	1.04	(0.44, 2.46)	0.0353	0.2669	8.95E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	4.34	(1.06, 17.88)	1.4689	0.4366	7.66E-04	3.22E-02
Cancer treated in the past year	1.66	(0.23, 12.21)	0.5094	0.6149	4.07E-01	1.00E+00
Cardiovascular disease	2.88	(1.03, 8.08)	1.0584	0.318	8.74E-04	3.67E-02
Chronic kidney disease	13.83	(3.59, 53.34)	2.6267	0.4165	2.85E-10	1.20E-08
Diabetes	3.53	(1.61, 7.75)	1.2624	0.2422	1.86E-07	7.82E-06
Hypertension	2.16	(1.09, 4.29)	0.7721	0.2113	2.59E-04	1.09E-02
Other	1.64	(0.58, 4.63)	0.4926	0.3206	1.24E-01	1.00E+00
Other autoimmune disease	1.28	(0.49, 3.36)	0.2478	0.2976	4.05E-01	1.00E+00
Other immunodeficiency disorder	2.16	(0.37, 12.54)	0.7723	0.542	1.54E-01	1.00E+00

Other lung condition	3.74	(1.01, 13.88)	1.3195	0.4045	1.10E-03	4.64E-02
Any	3.13	(1.52, 6.45)	1.1406	0.2233	3.25E-07	1.37E-05
OBESITY					li -	
obesity I (BMI >= 30 and BMI < 35)	1.24	(0.57, 2.68)	0.2116	0.2385	3.75E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.12	(0.48, 2.62)	0.1104	0.2632	6.75E-01	1.00E+00
obesity III (BMI >= 40)	1.5	(0.51, 4.38)	0.4053	0.3305	2.20E-01	1.00E+00
Not obese	1		0		nan	nan
GENETIC SEX					1	
Female	1		0		nan	nan
Male	1.53	(0.80, 2.94)	0.4266	0.2013	3.41E-02	1.00E+00
SYMPTOMS						
Abdominal pain	2.02	(1.01, 4.06)	0.7042	0.2147	1.04E-03	4.37E-02
Body aches	2.16	(0.95, 4.93)	0.7723	0.2541	2.37E-03	9.95E-02
Change in taste or smell	0.73	(0.37, 1.41)	-0.3191	0.2051	1.20E-01	1.00E+00
Chills	2.32	(1.14, 4.72)	0.8403	0.2196	1.30E-04	5.44E-03
Cough producing phlegm	1.89	(0.97, 3.66)	0.6342	0.2046	1.94E-03	8.13E-02
Diarrhea	2.33	(1.21, 4.48)	0.844	0.2021	2.96E-05	1.24E-03
Dry cough	2.69	(1.30, 5.56)	0.9909	0.2238	9.53E-06	4.00E-04
Feeling tired or fatigue	6.27	(0.93, 42.41)	1.8352	0.59	1.87E-03	7.84E-02
Fever	3.33	(1.50, 7.36)	1.2022	0.2449	9.18E-07	3.85E-05
Headache	0.86	(0.44, 1.70)	-0.1487	0.2098	4.78E-01	1.00E+00
Nasal congestion	0.92	(0.48, 1.80)	-0.0791	0.2053	7.00E-01	1.00E+00
Nausea or vomiting	2.43	(1.22, 4.84)	0.8874	0.2129	3.07E-05	1.29E-03
Runny nose	0.95	(0.45, 2.01)	-0.0495	0.2303	8.30E-01	1.00E+00
Shortness of breath	10.57	(3.99, 28.02)	2.3584	0.3007	4.35E-15	1.83E-13
Sore throat	1.27	(0.63, 2.57)	0.2369	0.2177	2.76E-01	1.00E+00

723

Unadjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening illness were calculated among those reporting a positive COVID-19 test result. The following groups served as reference populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).

731 Supplementary Table 20. Summary of risk factors and performances of different models

7	2	2
1	Э	3

Model	Risk Factors in Final Model	Holdout AUC (95% CI)
Susceptibility– symptoms excluded (Dem + Exp)	sex, aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Healthcare worker directly exposed, Household member tested positive, Household positive case count, Biological relative tested positive, Directly exposed to someone who tested positive	0.84 (0.82, 0.86)
Susceptibility– symptoms included (Dem + Exp + Symp)	sex, Fever, Runny nose, Sore throat, Feeling tired or fatigue, Change in taste or smell, aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Healthcare worker directly exposed, Household member tested positive, Household positive case count, Biological relative tested positive, Directly exposed to someone who tested positive	0.94 (0.92, 0.96)
Susceptibility– symptoms excluded, L1-penalized model across larger set of risk factors	aged 18-29 (Y/N), aged 30-49 (Y/N), aged 65+ (Y/N), Biological relative tested positive, Directly exposed to someone who tested positive, Hypertension, Healthcare worker directly exposed, Household positive case count, Household member tested positive, Health condition (Y/N if any)	0.86 (0.85, 0.87)
Susceptibility– symptoms included, L1-penalized model across larger set of risk factors	aged 18-29 (Y/N), aged 30-49 (Y/N), aged 65+ (Y/N), Biological relative tested positive, Directly exposed to someone who tested positive, Hypertension, Healthcare worker directly exposed, Household positive case count, Household member tested positive, Health condition (Y/N if any), Abdominal pain, Body aches, Change in taste or smell, Chills, Cough producing phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Headache, Nasal congestion, Nausea or vomiting, Runny nose, Shortness of breath, Sore throat	0.90 (0.86, 0.94)
Susceptibility– literature- based ''minimal'' model (HWF Exp + Symp)	Change in taste or smell, Household member tested positive, Directly exposed to someone who tested positive	0.90 (0.88, 0.93)
Susceptibility– literature- based ''symptoms-only'' model (HWF Symp)		0.87 (0.84, 0.90)
	Fever, Shortness of breath, Dry cough, Sore throat, Chills, Body aches, Change in taste or smell	
Severity– hospitalization	sex, Fever, Shortness of breath, Dry cough, Feeling tired or fatigue, Diarrhea, Obesity III (BMI >= 40), aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Health condition (Y/N if any)	0.87 (0.84, 0.90)
Severity– hospitalization, L1-penalized model across larger set of risk factors	aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), COPD (Chronic Obstructive Pulmonary Disease), Cancer (treated in the past year), Cardiovascular disease, Chronic kidney disease, Diabetes, Hypertension, Other, Health condition (Y/N if any), Abdominal pain, Chills, Cough producing phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Nausea or vomiting, Shortness of breath	0.87 (0.86, 0.88)
Severity- critical case	sex, Fever, Shortness of breath, Dry cough, Feeling tired or fatigue, Diarrhea, Obesity III (BMI >= 40), aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Health condition (Y/N if any)	0.90 (0.87, 0.93)
Severity– critical case, L1- penalized model across larger set of risk factors	aged 30-49 (Y/N), aged 65+ (Y/N), COPD (Chronic Obstructive Pulmonary Disease), Cardiovascular disease, Chronic kidney disease, Diabetes, Hypertension, Other lung condition, Health condition (Y/N if any), Seasonal flu, sex, Abdominal pain, Body aches, Chills, Cough producing phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Nausea or vomiting, Shortness of breath	0.89 (0.87, 0.91)

- 735 Risk factors for models were selected based on literature as well as nominally significant odds
- ratios within the training dataset (Methods). 95% confidence intervals for the area under the
- 737 curve (AUC) on the holdout dataset were estimated via bootstrapping (Methods).

739 Supplementary Table 21. Stratified holdout performance assessment for a COVID-19

740 susceptibility model built from age, sex, and exposures (Dem + Exp)

741

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	228	38	190	0.88 (0.82, 0.94)	0.89 (0.80, 0.99)	0.65 (0.59, 0.72)
All	4834	632	4202	0.84 (0.82, 0.86)	0.75 (0.72, 0.79)	0.76 (0.75, 0.78)
European Genetic Ancestry	3372	408	2964	0.84 (0.82, 0.87)	0.74 (0.70, 0.78)	0.79 (0.77, 0.80)
Admixed Amerindian Genetic Ancestry	410	73	337	0.80 (0.74, 0.86)	0.74 (0.64, 0.84)	0.71 (0.66, 0.75)
Other Genetic Ancestry	824	113	711	0.83 (0.78, 0.87)	0.77 (0.69, 0.85)	0.71 (0.68, 0.75)
Ages 18-29	340	74	266	0.83 (0.77, 0.89)	0.81 (0.72, 0.90)	0.65 (0.59, 0.71)
Ages 30-49	1744	270	1474	0.80 (0.77, 0.83)	0.82 (0.77, 0.86)	0.59 (0.56, 0.61)
Ages 50-65	1515	200	1315	0.85 (0.82, 0.88)	0.73 (0.67, 0.79)	0.81 (0.79, 0.83)
Ages 65+	1235	88	1147	0.81 (0.75, 0.87)	0.57 (0.47, 0.67)	0.96 (0.95, 0.97)
Female	3354	409	2945	0.83 (0.81, 0.85)	0.73 (0.68, 0.77)	0.77 (0.75, 0.79)
Male	1480	223	1257	0.85 (0.82, 0.88)	0.81 (0.76, 0.86)	0.75 (0.73, 0.77)

742

Case/control status is defined based on a self-reported COVID-19 positive test result. The Dem +
 Exp model includes questions about exposures, age, and sex (Supplementary Table 20). Metric
 performance columns reflect mean and nominal 95% confidence intervals for each metric on an

746 internal, independent holdout dataset (Methods). Cohort-level receiver operator characteristic

747 (ROC) curves were constructed from predicted class probabilities of models trained on the entire

training dataset (Methods).

751 Supplementary Table 22. Stratified holdout performance assessment for a COVID-19

susceptibility model built from age, sex, exposures, and symptoms (Dem + Exp + Symp)

753

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	96	12	84	0.96 (0.88, 1.00)	0.91 (0.75, 1.00)	0.92 (0.86, 0.98)
All	2047	229	1818	0.94 (0.92, 0.96)	0.85 (0.80, 0.89)	0.91 (0.90, 0.93)
European Genetic Ancestry	1457	146	1311	0.93 (0.90, 0.96)	0.83 (0.77, 0.90)	0.91 (0.90, 0.93)
Admixed Amerindian Genetic Ancestry	155	23	132	0.98 (0.95, 1.00)	0.96 (0.87, 1.00)	0.89 (0.84, 0.95)
Other Genetic Ancestry	339	48	291	0.94 (0.90, 0.99)	0.81 (0.70, 0.92)	0.93 (0.90, 0.96)
Ages 18-29	132	29	103	0.98 (0.95, 1.00)	0.93 (0.84, 1.00)	0.92 (0.87, 0.97)
Ages 30-49	582	77	505	0.96 (0.95, 0.98)	0.89 (0.82, 0.96)	0.88 (0.85, 0.91)
Ages 50-65	616	83	533	0.93 (0.90, 0.97)	0.84 (0.76, 0.92)	0.91 (0.88, 0.93)
Ages 65+	717	40	677	0.89 (0.83, 0.96)	0.72 (0.58, 0.86)	0.95 (0.93, 0.97)
Female	1380	139	1241	0.94 (0.91, 0.97)	0.86 (0.80, 0.92)	0.91 (0.89, 0.92)
Male	667	90	577	0.94 (0.90, 0.97)	0.83 (0.76, 0.91)	0.93 (0.91, 0.96)

754

Case/control status is defined based on self-reported COVID-19 positive test result. The Dem +
Exp + Symp model includes questions about exposures, age, sex, and five symptom questions
(Supplementary Table 20). Metric performance columns reflect mean and nominal 95%
confidence intervals for each metric on an internal, independent holdout dataset (Methods).
Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class
probabilities of models trained on the entire training dataset (Methods).

761 762

Supplementary Table 23. Stratified holdout performance assessment for a literature-based COVID-19 susceptibility model based on two exposures and one symptom (HWF Exp + Symp)

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	96	12	84	0.94 (0.84, 1.00)	0.92 (0.76, 1.00)	0.94 (0.89, 0.99)
All	2047	229	1818	0.90 (0.88, 0.93)	0.78 (0.73, 0.83)	0.94 (0.93, 0.95)
European Genetic Ancestry	1457	146	1311	0.89 (0.86, 0.92)	0.75 (0.68, 0.82)	0.94 (0.93, 0.95)
Admixed Amerindian Genetic Ancestry	155	23	132	0.94 (0.88, 1.00)	0.87 (0.73, 1.00)	0.92 (0.87, 0.97)
Other Genetic Ancestry	339	48	291	0.92 (0.87, 0.97)	0.79 (0.68, 0.90)	0.96 (0.94, 0.98)
Ages 18-29	132	29	103	0.92 (0.85, 0.99)	0.79 (0.65, 0.94)	0.96 (0.92, 1.00)
Ages 30-49	582	77	505	0.91 (0.86, 0.95)	0.82 (0.73, 0.91)	0.92 (0.90, 0.95)
Ages 50-65	616	83	533	0.91 (0.87, 0.95)	0.81 (0.73, 0.89)	0.93 (0.91, 0.95)
Ages 65+	717	40	677	0.85 (0.77, 0.92)	0.65 (0.50, 0.80)	0.96 (0.95, 0.98)
Female	1380	139	1241	0.91 (0.88, 0.94)	0.81 (0.75, 0.88)	0.94 (0.92, 0.95)
Male	667	90	577	0.89 (0.85, 0.94)	0.73 (0.64, 0.83)	0.95 (0.94, 0.97)

Case/control status is defined based on self-reported COVID-19 positive test result. The literature-based HWF Exp + Symp model contains two exposure questions and a question about

one symptom (change in taste or smell, Supplementary Table 20).¹⁸ Metric performance columns

reflect mean and nominal 95% confidence intervals for each metric on an internal, independent

holdout dataset (Methods). Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class probabilities of models trained on the entire training dataset (Methods).
781 Supplementary Table 24. Stratified holdout performance assessment for a literature-based

782 COVID-19 susceptibility model based on seven symptoms (HWF Symp)

- 783
- 784

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	96	12	84	0.90 (0.77, 1.00)	0.84 (0.62, 1.00)	0.92 (0.86, 0.98)
All	2047	229	1818	0.87 (0.84, 0.90)	0.75 (0.69, 0.80)	0.91 (0.90, 0.93)
European Genetic Ancestry	1457	146	1311	0.87 (0.83, 0.91)	0.75 (0.68, 0.82)	0.91 (0.89, 0.93)
Admixed Amerindian Genetic Ancestry	155	23	132	0.92 (0.85, 0.99)	0.87 (0.73, 1.00)	0.93 (0.89, 0.97)
Other Genetic Ancestry	339	48	291	0.83 (0.76, 0.91)	0.67 (0.53, 0.80)	0.92 (0.89, 0.95)
Ages 18-29	132	29	103	0.85 (0.75, 0.96)	0.79 (0.64, 0.95)	0.94 (0.90, 0.99)
Ages 30-49	582	77	505	0.89 (0.85, 0.93)	0.75 (0.66, 0.85)	0.88 (0.85, 0.91)
Ages 50-65	616	83	533	0.86 (0.80, 0.91)	0.75 (0.65, 0.84)	0.89 (0.87, 0.92)
Ages 65+	717	40	677	0.84 (0.76, 0.92)	0.70 (0.55, 0.85)	0.95 (0.93, 0.96)
Female	1380	139	1241	0.87 (0.83, 0.91)	0.76 (0.69, 0.83)	0.90 (0.88, 0.92)
Male	667	90	577	0.87 (0.83, 0.92)	0.73 (0.63, 0.82)	0.94 (0.92, 0.96)

Case/control status is defined based on self-reported COVID-19 positive test result. The
 literature-based HWF Symp model contains 7 symptoms most commonly associated with
 COVID-19 (Supplementary Table 20).¹⁸ Metric performance columns reflect mean and nominal
 95% confidence intervals for each metric on an internal, independent holdout dataset (Methods).
 Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class

probabilities of models trained on the entire training dataset (Methods).

Supplementary Table 25. Comparison between train and holdout performances for different risk models

Model	Train AUC (95% CI)	Holdout AUC (95% CI)
Susceptibility- no symptoms (Dem + Exp)	0.83 (0.81, 0.85)	0.84 (0.82, 0.84)
Susceptibility- with symptoms (Dem + Exp + Symp)	0.95 (0.93, 0.97)	0.94 (0.92, 0.96)
Susceptibility- literature-based "minimal" model (HWF Exp + Symp)	0.90 (0.88, 0.92)	0.90 (0.88, 0.93)
Susceptibility- literature-based "symptoms-only" model (HWF Symp)	0.87 (0.84, 0.90)	0.87 (0.84, 0.90)
Severity- hospitalization	0.85 (0.82, 0.88)	0.87 (0.84, 0.90)
Severity- critical case of COVID-19	0.90 (0.87, 0.93)	0.90 (0.87, 0.93)

Columns reflect mean and nominal 95% confidence intervals for the area under the curve (AUC)

of trained models on either the training or holdout dataset. Confidence intervals were estimated

via bootstrapping (Methods).

801 Supplementary Table 26. Stratified holdout performance assessment for models to predict

802 hospitalization amongst COVID-19 positive cases

803

cohort	N	ncase	ncontrol	Auc	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	110	20	90	0.81 (0.72, 0.90)	0.85 (0.68, 1.00)	0.71 (0.62, 0.80)
All	1793	191	1602	0.87 (0.84, 0.90)	0.83 (0.78, 0.88)	0.75 (0.73, 0.77)
European Genetic Ancestry	1133	120	1013	0.87 (0.84, 0.90)	0.82 (0.76, 0.89)	0.74 (0.72, 0.77)
Admixed Amerindian Genetic Ancestry	219	16	203	0.94 (0.90, 0.98)	0.93 (0.81, 1.00)	0.79 (0.74, 0.85)
Other Genetic Ancestry	331	35	296	0.85 (0.77, 0.93)	0.80 (0.67, 0.94)	0.75 (0.70, 0.80)
Ages 18-29	201	7	194	0.95 (0.91, 0.99)	0.85 (0.57, 1.00)	0.90 (0.85, 0.94)
Ages 30-49	705	49	656	0.87 (0.82, 0.93)	0.76 (0.63, 0.88)	0.85 (0.82, 0.88)
Ages 50-65	616	78	538	0.86 (0.81, 0.90)	0.86 (0.78, 0.94)	0.65 (0.61, 0.69)
Ages 65+	271	57	214	0.78 (0.72, 0.85)	0.86 (0.77, 0.95)	0.53 (0.47, 0.60)
Female	1166	118	1048	0.87 (0.83, 0.90)	0.80 (0.72, 0.87)	0.77 (0.74, 0.79)
Male	627	73	554	0.87 (0.83, 0.91)	0.89 (0.82, 0.96)	0.71 (0.67, 0.75)

804

Case/control status is defined based on self-reported hospitalization due to COVID-19-related
illness (Methods). Metric performance columns reflect mean and nominal 95% confidence
intervals for each metric on an internal, independent holdout dataset (Methods). Cohort-level
receiver operator characteristic (ROC) curves were constructed from predicted class probabilities
of models trained on the entire survey cohort (Methods).

812 Supplementary Table 27. Stratified holdout performance assessment for models to predict

813 critical COVID-19 cases amongst all COVID-19 positive cases

814

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	110	15	95	0.87 (0.78, 0.97)	0.93 (0.80, 1.00)	0.75 (0.66, 0.83)
All	1793	105	1688	0.90 (0.87, 0.93)	0.93 (0.87, 0.98)	0.79 (0.77, 0.81)
European Genetic Ancestry	1133	70	1063	0.90 (0.86, 0.93)	0.90 (0.83, 0.97)	0.79 (0.76, 0.81)
Admixed Amerindian Genetic Ancestry	219	7	212	0.92 (0.88, 0.96)	1.00 (0.60, 1.00)	0.83 (0.78, 0.88)
Other Genetic Ancestry	331	13	318	0.92 (0.87, 0.97)	1.00 (0.73, 1.00)	0.77 (0.73, 0.82)
Ages 18-29	201	2	199	0.96 (0.92, 0.99)	1.00 (0.29, 1.00)	0.92 (0.88, 0.96)
Ages 30-49	705	24	681	0.94 (0.92, 0.96)	1.00 (0.84 1.00)	0.84 (0.81, 0.87)
Ages 50-65	616	43	573	0.87 (0.82, 0.93)	0.91 (0.82, 0.99)	0.71 (0.68, 0.75)
Ages 65+	271	36	235	0.84 (0.78, 0.91)	0.89 (0.78, 0.99)	0.71 (0.66, 0.77)
Female	1166	60	1106	0.90 (0.86, 0.94)	0.93 (0.87, 1.00)	0.80 (0.77, 0.83)
Male	627	45	582	0.89 (0.85, 0.93)	0.91 (0.83, 0.99)	0.77 (0.73, 0.80)

815

816 Case/control status is defined based on self-reported critical case progression among all COVID-

817 19 cases. Here, a critical case is defined based on self-reported ICU admittance, respiratory 818 failure, organ failure, or septic shock resulting from COVID-19-related illness (Methods). Metric 819 performance columns reflect mean and nominal 95% confidence intervals for each metric on an 820 internal, independent holdout dataset (Methods). Cohort-level receiver operator characteristic 821 (ROC) curves were constructed from predicted class probabilities of models trained on the entire

822 survey cohort (Methods).

823

824

Supplementary Figures 826



Cancer treated in the past year COPD Chronic Obstructive Pulmonary Disease

Other immunodeficiency disorder

828 Supplementary Figure 1. Severity (critical case) odds ratios (ORs) and 95% confidence 829 intervals (CIs) estimated from simple ("Unadjusted models," grey) and multiple 830 ("Adjusted models," black) logistic regression with adjustment for other risk factors. Open 831 circles indicate not significant (p-value > 0.05) after accounting for multiple hypothesis tests 832 using Bonferroni correction. Age, sex, genetic ancestry, and obesity ORs were estimated in 833 relation to the reference variables indicated. Exposure, health, and symptom ORs were each estimated separately as binary variables. Symptom ORs were estimated as binary variables 834 835 among symptomatic testers only (Methods). Risk factor adjustments for severity include: sex, 836 age, obesity (Y/N), and underlying health conditions (Y/N) if any).







Supplementary Figure 2: Comparison of Susceptibility and Severity adjusted ORs. Comparison of susceptibility ORs (horizontal axis) and severity ORs (vertical axis) from Figures 1 and 2. Severity aORs are for hospitalization. aORs are adjusted as in Figures 1 and 2 (see Fig 3 for adjusted ORs for symptoms). Plotted on a log scale for visibility. (a) Demographics, broken down by age, sex, and genetic ancestry. (b) Health conditions: Some pre-existing health conditions have increased odds of critical outcomes but susceptibility is not characterized by health conditions. (c) Exposures are important for susceptibility but not severity.





Supplementary Figure 3. Performance of susceptibility models evaluated in a symptomatic cohort of positive and negative testers. Plot depicts receiver operating characteristic (ROC) curves for four susceptibility models (Supplementary Table 20). Here, the modeling cohort has been restricted to positive and negative testers reporting at least one symptom of moderate or greater intensity for model training and evaluation.



Supplementary Figure 4. Severity Models Excluding Dyspnea (Shortness of Breath). a)
Receiver operating characteristic (ROC) curves for severity models to predict either critical
illness progression (black) or hospitalization (red) among COVID-19 positive cases. The models
here are built with the same risk factors as in Figure 4 with the exclusion of dyspnea (shortness
of breath). b) Classification confusion matrix for severity models. Refer to Methods as well as
Supplementary Tables 20 for additional model risk factor information.

864 **References**

- 1. Williamson, E. J. et al. Factors associated with COVID-19-related death using
- 866 OpenSAFELY. *Nature* **584**, 430–436 (2020).
- 867 2. World Health Organization. Coronavirus Disease (COVID-19)– Weekly Epidemiological
- 868 Update. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201005-
- 869 weekly-epi-update-8.pdf (2020).
- 870 3. U.S. Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID-
- 871 19): CDC COVID data tracker. https://covid.cdc.gov/covid-data-
- 872 tracker/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-
- 873 ncov%2Fcases-updates%2Fcases-in-us.html#cases (2020).
- 4. CMMID COVID-19 working group et al. Age-dependent effects in the transmission and
- 875 control of COVID-19 epidemics. *Nat. Med.* **26**, 1205–1211 (2020).
- 5. Yale IMPACT research team *et al.* Sex differences in immune responses that underlie
- 877 COVID-19 disease outcomes. *Nature* (2020) doi:10.1038/s41586-020-2700-3.
- 878 6. Roberts, G. H. L. & Park, D. S. AncestryDNA COVID-19 Host Genetic Study Identifies
- 879 Three Novel Loci. *medRXiv* (2020).
- 880 7. Zhao, Y. et al. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2.
- 881 *medRXiv* (2020) doi:10.1101/2020.01.26.919985.
- 882 8. Liu, Y. et al. Association between age and clinical characteristics and outcomes of COVID-
- 883 19. Eur. Respir. J. 55, 2001112 (2020).
- 9. Li, X. *et al.* Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.
- 885 *J. Allergy Clin. Immunol.* **146**, 110–118 (2020).

- 886 10. Clark, A. et al. Global, regional, and national estimates of the population at increased risk of
- severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet*

888 *Glob. Health* **8**, e1003–e1017 (2020).

- 11. Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R. & Klein, S. L. Impact of
- sex and gender on COVID-19 outcomes in Europe. *Biol. Sex Differ.* **11**, 29 (2020).
- 891 12. Grasselli, G. et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With
- 892 SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 323, 1574 (2020).
- 13. Richardson, S. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700
- Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **323**, 2052 (2020).
- 895 14. Guan, W. *et al.* Comorbidity and its impact on 1590 patients with COVID-19 in China: a
 896 nationwide analysis. *Eur. Respir. J.* 55, 2000547 (2020).
- 15. Ellinghaus, D. et al. Genomewide Association Study of Severe Covid-19 with Respiratory
- Failure. *N. Engl. J. Med.* NEJMoa2020283 (2020) doi:10.1056/NEJMoa2020283.
- 899 16. Wynants, L. et al. Prediction models for diagnosis and prognosis of covid-19: systematic
- 900 review and critical appraisal. *BMJ* m1328 (2020) doi:10.1136/bmj.m1328.
- 901 17. Menni, C. *et al.* Real-time tracking of self-reported symptoms to predict potential COVID902 19. *Nat. Med.* 26, 1037–1040 (2020).
- 903 18. Allen, W. E. et al. Population-scale longitudinal mapping of COVID-19 symptoms,
- 904 behaviour and testing. *Nat. Hum. Behav.* **4**, 972–982 (2020).
- 905 19. Martin, L. M., Leff, M., Garrett, C. & Nelson, D. E. Validation of self-reported chronic
- 906 conditions and health services in a managed care population. *Am J Prev Med* **18**, 215–8
- 907 (2000).

- 908 20. Nguyen, L. H. et al. Risk of COVID-19 among front-line health-care workers and the
- general community: a prospective cohort study. *Lancet Public Health* **5**, e475–e483 (2020).
- 910 21. Stokes, E. K. et al. Coronavirus Disease 2019 Case Surveillance United States, January
- 911 22–May 30, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 759–765 (2020).
- 912 22. Chow, E. J. et al. Symptom Screening at Illness Onset of Health Care Personnel With SARS-
- 913 CoV-2 Infection in King County, Washington. JAMA 323, 2087 (2020).
- 914 23. Shi, L., Wang, Y., Wang, Y., Duan, G. & Yang, H. Dyspnea rather than fever is a risk factor
- 915 for predicting mortality in patients with COVID-19. J. Infect. S0163445320302887 (2020)
- 916 doi:10.1016/j.jinf.2020.05.013.
- 917 24. Jehi, L. *et al.* Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing.
 918 *Chest* S0012369220316548 (2020) doi:10.1016/j.chest.2020.05.580.
- 919 25. Barreto, M. L. Infectious diseases epidemiology. *J. Epidemiol. Community Health* 60, 192–
 920 195 (2006).
- 921 26. Rosenberg, A., Keene, D. E., Schlesinger, P., Groves, A. K. & Blankenship, K. M. COVID-
- 922 19 and Hidden Housing Vulnerabilities: Implications for Health Equity, New Haven,
- 923 Connecticut. *AIDS Behav.* **24**, 2007–2008 (2020).
- 924 27. Price-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization and Mortality
- among Black Patients and White Patients with Covid-19. N. Engl. J. Med. 382, 2534–2543
 (2020).
- 927 28. Millett, G. A. *et al.* Assessing differential impacts of COVID-19 on black communities. *Ann.*928 *Epidemiol.* 47, 37–44 (2020).
- 929 29. Webb Hooper, M., Nápoles, A. M. & Pérez-Stable, E. J. COVID-19 and Racial/Ethnic
- 930 Disparities. *JAMA* **323**, 2466 (2020).

- 30. Julie Bosman & Mervosch, S. As virus surges, younger people account for 'disturbing'
- number of cases. *The New York Times* (2020).
- 933 31. Jehi, L. et al. Development and validation of a model for individualized prediction of
- hospitalization risk in 4,536 patients with COVID-19. *PLOS ONE* **15**, e0237419 (2020).
- 935 32. Dietz, W. & Santos 🗆 Burgoa, C. Obesity and its Implications for COVID 🗆 19 Mortality.
- 936 *Obesity* **28**, 1005–1005 (2020).
- 937 33. U.S. Centers for Disease Control and Prevention (CDC). Coronavirus disease: people with
- 938 certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-
- 939 precautions/people-with-medical-
- 940 conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F20
- 941 19-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html (2020).
- 942 34. U.S. Centers for Disease Control and Prevention (CDC). Coronavirus disease: scientific
- 943 evidence for conditions that increase risk of severe illness.
- 944 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html
- 945 (2020).
- 35. Han, E. *et al.* Clustering of 770,000 genomes reveals post-colonial population structure of
- 947 North America. *Nat. Commun.* **8**, 14238 (2017).
- 948 36. Ball, C. A. Ethnicity Estimate 2019 White Paper.
- 949 https://www.ancestrycdn.com/dna/static/pdf/whitepapers/EV2019_white_paper_2.pdf
- 950 (2019).
- 37. Hastie, T. *The Elements of Statistical Learning: Data Mining, Inference, and Prediction.*(Springer, 2009).

- 953 38. U.S. Centers for Disease Control and Prevention (CDC). Symptoms of Coronavirus.
- 954 https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (2020).
- 955 39. Jing, Q.-L. et al. Household secondary attack rate of COVID-19 and associated determinants
- 956 in Guangzhou, China: a retrospective cohort study. *Lancet Infect. Dis.* S1473309920304710
- 957 (2020) doi:10.1016/S1473-3099(20)30471-0.
- 958 40. Hu, Z. et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened
- among close contacts in Nanjing, China. 6 (2020).